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Introduction: Vitamin D deficiency has been associated with decreased overall survival in 
patients with diffuse large B-cell lymphoma treated with rituximab. Natural killer cell-mediated 
antibody-dependent cytotoxicity is one of the main mechanisms of action of rituximab, and it 
has been shown to be enhanced after in vivo vitamin D supplementation. This effect was more 
pronounced in females. We aimed to explore molecular mechanisms behind these findings 
using whole transcriptome analysis of natural killer cells after vitamin D supplementation. 
Methods: Natural killer cells were isolated by magnetic depletion from eight otherwise healthy 
subjects (four females and four males) with vitamin D deficiency, before and after vitamin D 
supplementation to a target serum level of 65 ng/ml. RNA was extracted followed by whole 
transcriptome microarray analysis. Results were verified by quantitative polymerase chain 
reaction. For differential expression analysis, the paired t-test and two-way ANOVA were used. 
Comparisons were made with regard to both vitamin D status and sex. In addition, pathway 
analysis using gene set enrichment analysis was performed.  
Results: After correction for multiple testing no genes showed statistically significant 
differential expression in the sex-independent comparison. For hypothesis generation, genes 
with an unadjusted p-value < 0.01 are reported (n = 505). An impact on known vitamin D-
dependent genes was demonstrated. Genes involved in cytokine signaling like IFNL3 and IL-
2RB were found to be upregulated, while others like IFNG and TLR genes were downregulated. 
In the sex-dependent analysis 28 transcripts with statistically significant sex- and vitamin D-
dependent expression after adjustment were identified, like the JPX gene which was 
upregulated in females. Pathway analysis highlighted the role of interferon-α genes (IFNA2, -
A4, -A6, -A8, -A10) in statistically significantly upregulated pathways. Other pathways involved 
in the immune response were found to be significantly downregulated, mainly by 
downregulation of the TLR2, -5, -7 and -8 genes. Finally, the ubiquitin ligase pathway was 
found to be downregulated. 
Conclusion: Vitamin D supplementation has only a slight effect on the natural killer cell 
transcriptome and the small sample size used in this study limits detection of such subtle 
changes. Our results implicate a role for vitamin D in gene expression involving the toll-like 
receptor and type I/III interferon axis and its regulation through the ubiquitin ligase system. 
IFN-γ downregulation may well be consistent with the observation of increased lymphoma 
killing of natural killer cells. JPX-dependent epigenetic regulation of X-chromosome 
deactivation in females could explain the downregulation of genes like TLR7 and -8 which are 
located on the X-chromosome. It is also possible, that vitamin D exerts its effects on natural 





2.1  NATURAL KILLER CELLS 
Natural killer (NK) cells are large granulated lymphocytes playing a key role in the innate 
immune response. Their name implies their ability to kill virally infected cells and tumor cells 
without prior sensitization [51]. Their functions include secretion of cytokines and direct 
cytotoxic effects [145] as well as a key role in homeostasis through elimination of degenerate 
or malignant cells. They make up 2-18 % of lymphocytes in the peripheral blood [129]. NK cells 
lack a highly variable antigen-specific surface receptor resulting from rearrangement of 
immunoglobulin-like genes as known from B cells (B cell receptor) or T cells (T cell receptor) 
[26]. In lieu thereof, they express CD16 and CD56 as well as other inhibitory and stimulatory 
receptors, which working closely with toll-like receptors and other pattern recognition receptors 
to regulate NK-cell activity. The resulting equilibrium between activating and inhibitory signals 
mandates NK cell activation and target cell lysis [149]. 
2.1.1 Subsets of NK Cells 
Human NK cells can be divided into two categories due to the expression of the two surface 
molecules CD16 (low-affinity Fcγ receptor III, FcγRIII) and CD56. It is possible, that these two 
populations represent different stages of differentiation [124].   
2.1.1.1 Cytotoxic CD56dim, CD16high NK Cells 
These NK cells circulate in the peripheral blood, accounting for up to 90 % of the NK cells in 
the peripheral blood and spleen [150]. Their cytotoxic activity is mediated by perforin and 
granzymes in a similar mechanism as in cytotoxic CD8+ T lymphocytes. After contacting the 
target cell, perforin induces pore formation in the membrane of the target cell upon 
polymerization, enabling the entrance of granzymes and granulysin into the interior 
[26,51,124,145,150] of the target cell. NK-cell-mediated cytotoxicity is described in detail in the 
next chapter. Another mechanism of cytotoxicity is the induction of apoptosis via the TRAIL or 
Fas pathway [26]. CD16 allows NK cells specifically to identify antigens marked with 
corresponding antibodies. Via this CD16/antibody binding, the NK cell can directly contact cells 
expressing a corresponding antigen on their surface, thus inducing the so-called antibody-
dependent cell-mediated cytotoxicity (ADCC). Furthermore, CD56dim/ CD16high NK cells are 
able to produce different cytokines such as IFN-γ, TNF-β, and GM-CSF which activates 
macrophages at sites of infection [5]. This interaction between NK cells and macrophages 




T-cell-mediated adaptive immunity develops and ultimately takes over the eradication of the 
pathogens. 
2.1.1.2 Immunomodulatory CD56bright, CD16dim NK Cells 
They are primarily located in the lymph nodes. Their primary function is the modification of type 
1 T-helper cell (Th1) immune responses, the activation of macrophage-driven killing of obligate 
intracellular pathogens and to induce anti-proliferative effects on viral- and malignant-
transformed cells through IFN-γ secretion [26,47,96]. Other effects of IFN-γ-secreting NK cells 
include the activation of antigen-presenting cells (APC) especially by enhancing MHC I 
expression [26]. IFN-γ is secreted in response to stimulation with the interleukins (IL) IL-12, IL-
15, and IL-18. CD56bright/CD16dim NK cells also secrete other cytokines like tumor necrosis 
factor (TNF)-α, TNF-β, GM-CSF, or IL-10. Under activation by cytokines like IL-2 and IL-15 
they can furthermore induce cytotoxicity comparable to CD56dim/ CD16high NK cells. Lastly,  
these NK cells can also differentiate to CD56dim/ CD16high NK cells, leaving the lymph node to 
circulate in the peripheral blood [26]. 
2.1.1.3 Natural Killer T Cells 
Natural killer T (NKT) cells represent a very small subset of human lymphocytes (< 1 %) which 
exhibit T cell as well as NK cell phenotype and function. They express both NK cell markers 
such as CD161 and CD94, as well as a T-cell receptor (TCR) alpha/beta. This TCR however 
does not recognize antigens presented MHC-I- or -II-molecules. It is a semi-invariant TCR that 
only interacts with glycolipids presented by CD1d, a non-classical antigen-presenting molecule 
[17]. Upon stimulation they produce a variety of cytokines which include IFN-γ, TNFs, IL-2, IL-
4, IL-10, IL-13, IL-17, and transforming growth factor (TGF)-β [159]. 
2.1.2 NK-Cell-mediated Cytotoxicity 
Cytotoxic cells employ various agents for lysing their target cells. 
2.1.2.1 Perforin 
Perforin is a cytolytic protein found in granules of cytotoxic CD8+ T lymphocytes and NK cells. 
During degranulation, it perforates the cell membrane of the target cell by forming a pore. It 
has been shown to play a role in antiviral immune response, elimination of tumor cells as well 
as allograft rejection [66,103]. The structural similarity of perforin with the bacterial cholesterol-
dependent cytolysins has allowed a better understanding of its mechanism of action. After 
Ca2+-dependent binding to the target cell membrane, cholesterol-dependent cytolysins and 




helices (named TMH1 and TMH2) unwind and insert as amphipathic β-strands into the target 
membrane, thus forming the full pore [82].  
Recent advances have shed light to the transcriptional regulation of the perforin gen (PRF1). 
Ten DNase I hypersensitivity sites have been identified in its locus control region [117], 
including binding sites for runt-related transcription factor 3 (RUNX3) and eomesodermin 
(eomes) [151].  
2.1.2.2 Granzymes 
Granzymes are serine proteases, which are stored in intercellular granules of cytotoxic 
T lymphocytes and NK cells. There are eleven different granzymes (A, B, C, D, E, F, G, H, K, 
M, and N), but only five of these have been shown to be expressed in humans (A, B, H, K and 
M) [131]. Granzymes do not act by untargeted protein digestion. Their general mechanism of 
function is the coordinated activation of caspases, triggering specific cell death pathways, such 
as apoptosis. Although many in vitro experiments have demonstrated cytolytic activity, their 
exact pathophysiological role remains unclear, as granzyme deficiency does not lead to any 
known human disease [139]. Knock out studies in mice have demonstrated that loss of perforin 
negates granzyme-induced apoptosis, whereas single granzyme gene disruption results in a 
defect but not in loss of the cytotoxic NK cell activity. 
2.1.2.3 Granulysin 
Granulysin is another cytotoxic agent found in the granules of NK cells and cytotoxic T 
lymphocytes. It is a member of the saposin-like protein family including NK lysin and 
amoebapores. Positively charged residues of the molecule interact with the negatively charged 
target cell membrane or the bacterial cell wall, respectively, leading to increased permeability 
und cell lysis [34,69]. In tumor cells, granulysin induces sphingomyelinase-dependent 
apoptosis [35]. Granulysin gene (gnly) expression is dependent on the transcription factors 
AP-1 and C/EBPb. Furthermore, its expression is upregulated under stimulation with IL-2 or 
bacterial antigen [81]. 
2.1.2.4 Granule Exocytosis 
A shift of the balance of inhibitory and activating signals toward NK-cell activation results 
primarily in a considerable increase in cytosolic Ca2+ concentration. The next step is the 
intracellular polarisation of the microtubule-organizing center toward the target cell. The 
cytotoxic granules move along this structure until they fuse with the cell membrane of the NK 
cell, thus releasing their content into the synaptic cleft. Disorders of the cytoskeleton result in 




Wiskott-Aldrich syndrome results in such a NK-cell defect. Similarly, mutations of adhesion 
molecules as in the leukocyte adhesion deficiency syndromes 1 and 3 [76,140], or in case of 
the autosomal recessive hyper-IgE-recurrent infection syndrome (AR-HIES) with a defect of 
the gene encoding the dedicator of cytokinesis 8 (DOCK8) leading to impaired defense against 
viral and bacterial infections. It is assumed that the NK cell protects itself from the content of 
its granules by secretion of serpin B9.  
2.1.3 Regulation of NK-Cell Activity – NK-Cell Receptors 
Activation of NK cells is induced by the interleukins IL-2, IL-12, IL-15, IL-18, and interferon-α/β 
[153],[79]. These cytokines along with interactions with cells in the microenvironment like 
dendritic cells (DC), macrophages and T cells determine the extent of the cytolytic activity of 
NK cells [95]. Finally, the cytotoxic activity depends on the balance of inhibitory and promoting 
interactions with the microenvironment but also with the target cells. Binding of inhibitory 
receptors to MHC class I molecules block NK-cell effector function, although some non-MHC 
class I inhibitory ligands can be recognized too.  
There are two types of inhibitory receptor families in humans: killer cell Ig-like receptors (KIR) 
and the CD94/NKG2A lectin-like receptors. 
NK cells express several activating receptors simultaneously. These include natural-killer 
group 2 member D (NKG2D), activating KIRs, NKp80, NKp30, NKp44, NKp46, CD94/NKG2C, 
DNAX accessory molecule (DNAM)-1 and 2B4 [73].  
NK cells derived from humans and mice express different receptors, and this has complicated 
research in this area. In this thesis, only NK-cell receptors expressed in humans are described. 
Table 1 provides an overview. 
2.1.3.1 Killer Inhibitory Receptors (KIR) 
Located superficially on the NK cell, KIRs represent a family of inhibitory as well as activating 
receptors binding specifically to MHC class I molecules [21,39,79]. MHC-I-molecules are 
expressed constitutively on every nucleated healthy cell indicating the affiliation to the host’s 
immune system. In contrast, the lack of expression or even a complete missing on the cell 
surface indicates a “missing self” status and is always associated to profound changes in the 
cell function/phenotype, such as a viral infection or a malignant transformation. The type and 
number of extracellular immunoglobulin domains define the specificity of KIRs, whereas their 
function as activating or inhibitory receptors is mediated through their intracellular domains: 
short “S” = activating or long “L” = inhibitory [79]. These characteristics are reflected in the 
nomenclature, for example, KIR2DS1, KIR3DL1, or KIR3DS1. Activating KIR signals using the 
short intracellular domain are initiated by the adapter protein DAP12, while inhibitory KIR are 




long domain. Various KIRs bind to HLA-A (e.g. KIR3DL2 to HLA-A3 und HLA-A1), to HLA-B 
(e.g. KIR3DL1 to HLA-Bw4) or HLA-C (e.g. KIR2DL1 to HLA-C2). Each NK cell is equipped 
with an individual KIR repertoire, and it undergoes a selection process to ensure that it 
expresses one KIR for each HLA class I molecule. Furthermore, there are significant 
polymorphisms in KIR haplotypes in each individual. The KIR haplotype “A” is associated with 
few or no activating KIRs, whereas haplotype “B” contains a number of activating KIRs. NK 
cells which lack KIR inhibitory receptors express the inhibitory receptor CD94/NKG2A whose 
function is HLA-E dependent, as explained below (2.1.3.36) [122]. 
2.1.3.2 Natural Cytotoxicity Receptors (NCR):  
The NCRs (NKp30, NKp44, NKp46 and NKp80) belong to the immunoglobulin superfamily and 
recognize various stress signals and viral as well as tumor cell ligands. 
NKp30 associates with immunoreceptor tyrosine-based activation motif (ITAM) to initiate 
signal transduction. Three isoforms of NKp30 exist: NKp30a, NKp30b, and NKp30c, with 
NKp30a and NKp30b being stimulatory, whereas NKp30c is immunosuppressive. NKp30 
recognizes tumor antigens and binds several viral ligands including the protein pp65 of the 
cytomegaly virus (CMV).  
NKp44 is coupled to a dimer of the ITAM-containing adaptor DNAX-activation protein 12 
(DAP12) for downstream signal transduction. Ligands include cellular proteoglycans, influenza 
virus hemagglutinin and other viral hemagglutinins–neuraminidase proteins as well as 
elements of the bacterial cell wall.  
NKp46 is the most specific marker of NK cells. For signaling, NKp46 associates with CD3ζ 
and with the γ-chain of FcγRI. Activating ligands include viral hemagglutinins-neuraminidase 
proteins, expressed on pancreatic β-cells (which can lead to type I diabetes upon activation) 
as well as not yet completely characterized ligands on normal and on tumor cells [73].                                                                                                                                                                                                                                                                                                                                                                                
2.1.3.3 The NKG2-receptor family 
The NKG2-receptors are C-Type lectin-receptors which dimerize with a CD94 molecule before 
binding to atypical MHC-I molecules expressed on target cells. 
NKG2A/C/E: They are expressed as heterodimers with CD94 on the cell surface and bind on 
HLA-E. CD94–NKG2C and CD94–NKG2E have been shown to associate also with DAP-12 
and therefore playing an activating role. The CD94–NKG2A receptors are important inhibitors 
of NK cell function which also bind to HLA-E. Their inhibitory activity is associated with the 




NKG2D: Contrary to the other NKG2-receptor family members, does not bind to CD94. 
Instead, it is expressed as a homodimer. Its downstream signaling involves association with 
DAP-10 molecules to induce a cytotoxic response. It recognizes several ligands including MHC 
class I chain-related protein MIC-A, MIC-B, and UL16-binding proteins (ULBP1-4). Expression 
of MIC-A and MIC-B has been reported to be induced upon malignant transformation or cellular 
stress as a result of the DNA damage response pathway and/or the heat shock response 
pathway. Its activation enables NK cells to recognize “stressed cells”[114]. 
2.1.3.4 NKRP1 receptor family 
NKp80 is a C-type-lectin-like receptor similar to the NKG2-receptor family discussed above. It 
binds an activation-induced C-type lectin (AICL) receptor, which is often expressed by 
monocytes, operating as a bridge for mutual crosstalk between NK and myeloid cells [79]. 
NKp65 induces cytotoxicity and secretion of IFN-γ when it encounters its ligand keratinocyte-
associated C-type lectin (KACL). Both NKp65 and NKp80 contain a hemITAM cytoplasmatic 
domain which is used in Syk-dependent downstream signaling [14]. 
NKRP1A has an inhibitory function. It inhibits IFN-γ production and NK cell activation when in 
encounters activated leukocytes expressing lectin-like transcript 1 (LLT1). Intracellular 
signaling is mediated through a cytoplasmatic ITIM domain which recruits Src homology 2-
containing protein tyrosine phosphatase-1 (SHP-1) [14]. 
2.1.4 Toll-Like Receptors 
The immune system of the vertebrates must be able to respond to bacterial, viral, and fungal 
infections. This function depends on molecular patterns unique to each pathogen class known 
as pathogen-associated molecules (PAMP). Cells of the innate immune system express 
pattern recognition receptors (PRR) which are responsible for the recognition of PAMPs as a 
sign of infection and consequent initiation of the innate immune response. The toll-like 
receptors (TLR) are the most studied class of such PRRs in mammals. TLRs are not only 
expressed differently by different cells of the innate immune system, but also by the different 
cell types themselves in terms of where they are expressed: either on the cell surface (TLR1, 
2, 4-6, 10, 11), within endosomes (TLR3, 7-9, 12, 13), or intracellular (TLR2 and TLR4 in 
endothelial, dendritic and epithelial cells) [1]. The TLR1, 2, 4, 5 and 6 are mainly responsible 
for the recognition of bacterial-derived patterns. There is no risk of cross-reaction with the host, 
since bacterial PAMPs are very specific. In contrast, the recognition of viral-derived PAMPs, 
mostly nucleic acid fragments, takes place via TLR3, 7, 8 and 9. However, since these nucleic 
acid sequences are not always virus-specific, their TLRs are not expressed on the surface but 




DNA leading to autoimmunity [60]. In pooled human NK cells (CD3-/CD56+) as well as in NK-
T-like cells (CD3+/CD56+) mRNA of TLRs 1-9 has been detected [133,134]. Upon TLR 
activation, NK cells produce cytokines like IFN-α, granulocyte macrophage colony-stimulating 
factor, which are necessary to fight infection but also can cause deleterious inflammation if 
excreted in excessive amounts [1]. 
2.1.5 Antibody-Dependent Cytotoxicity  
Antibody-dependent cytotoxicity (ADCC) is a separate way of NK cells to mediate cytotoxicity 
that combines elements from the innate and the adaptive/humoral immune system. CD16 (low-
affinity Fc-γ receptor III, FcγIIIa) on the NK-cell surface bind to the Fc part of an antibody. 
Through their Fab part, antibodies also bind cell-bound antigens and thus antibodies can build 
a bridge between the NK cell with its CD16 receptor on one side and a target cell with a specific 
surface antigen on the other side. Like "normal" cytotoxic activity, NK cell-mediated ADCC is 
under control of the ratio of activating and inhibiting receptors stimulated by their respective 
ligands on the target cell. In addition, cytokines also influence NK cell activity. Thus, IL-2, IL-
12 or IL-21 enhance ADCC [123]. ADCC is being widely exploited therapeutically by the use 
of monoclonal antibodies (mAb), for example in breast cancer by anti-HER2-mAb 
(Trastuzumab), in head and neck cancer by anti-HER1-mAb (Cetuximab) and lymphoma by 
anti-CD20-mAb (Rituximab and Obinutuzumab) [8,77,156]. 
2.1.5.1 CD16, Low Affinity Receptor for IgG (FcγRIIIa) 
The most studied membrane receptor on NK cells is the CD16 molecule or Fc-γ receptor III 
(FcγRIIIa), a member of the immunoglobulin superfamily. The receptor is also present on 
monocytes and some T-cell subsets.  Some NK cells also express FcγRIIc (CD32c), which is 
similarly involved in ADCC. FcγRIIIa is associated with the γ-subunit of the high-affinity IgE 
receptor (FcγRI-ε) and the ζ-subunit of T-cell receptor (TCR), or CD3ζ. Downstream signaling 
after contact with CD16 ligands is mediated through activation of immunoreceptor tyrosine-
based activation motifs (ITAM) and leads to stimulation of the phosphatidylinositol 3-kinase 
(PI3K), mitogen-activated protein kinase (MAPK), ZAP70-phosphorylation, activation of 
phospholipase Cγ1 Cγ2, activation of p21 ras and nuclear translocation and activation of 
NFATp and NFATc (NFAT: nuclear factor of activated T cells). This results in cytokine release, 
NK-cell degranulation and signaling through TNF family death receptors leading finally to target 
cell lysis. Furthermore, secreted IFN-γ activates nearby immune cells  and promotes antigen 
presentation and adaptive immune responses [79],[155]. CD16 is only associated in ADCC 
and is not involved in other forms of NK cell-mediated cytotoxicity [79]. The efficacy of rituximab 




Specifically, the 158-valine and 158-phenylalanine variants have predictive value in the 
outcome of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab [2].  
Table 1: Human NK cell receptors 
Receptor 
families 






FcRγ and CD3ζ, 
ZAP70/Syk 
NKp44 NKp44L DAP12, ZAP70/Syk 
NKp30a, b 




NKp44 PCNA ITIM, SHP1, 2 
NKp30c unknown unknown 
NKG2 
Activating 
NKG2D MICA/B, ULBP1-6 DAP10, Grb2, Vav, SOS 
CD94/NKG2C HLA-E DAP12, ZAP70/Syk 
Inhibitory 
CD94/NKG2A 









ITIM, SHP1, 2 3DL1/L2/L3 HLA- A, -B 
3DL1/L2/L3 HLA- A, -B 
FcγRIIIa Activating CD16 Fc IgG 
FcRγ and CD3ζ, 
ZAP70/Syk 
NKRP1 
Activating NKp80 AICL hemITAM/Syk 
Activating NKp65 KACL hemITAM/Syk 
Inhibitory NKRP1A LLT1 ITIM, SHP1 
Adapted from Konjević et al [74]. 
2.2 VITAMIN D  
Vitamin D is a member of the secosteroid hormones and essentially regulates calcium, 
phosphate, and bone metabolism. In addition, many non-skeletal, sometimes systemic effects 
have been described in recent years. New vitamin D effects have been hypothesized by 
experimental, genetic, clinical and epidemiological studies as well as a number of meta-
analyses, but their practical significance is still unclear. It is both supplied through the diet and 




(UVB). The dietary intake of usual foods is not sufficient to reach the estimated value for an 
adequate intake in the absence of endogenous synthesis [55]. 
2.2.1 Synthesis and Metabolism of Vitamin D 
Humans synthesize vitamin D in their skin after exposure to sunlight. Steroids are composed 
of four combined ring structures named A to D. Solar UVB radiation (wavelength 290 to 315 
nm) opens the B-ring of provitamin D3 (7-dehydrocholesterol) and converts it non-
enzymatically to previtamin D3. This spontaneously isomerises under the effect of heat and it 
is further converted to vitamin D3 (cholecalciferol). Excessive exposure to sunlight causes 
degradation of the provitamin D3 and vitamin D3 to inactive photoproducts, so an accumulation 
to toxic levels through sun exposure is not possible. Another source of vitamin D is dietary 
uptake, either as vitamin D3 mainly from fish oil, or in form of vitamin D2 (ergocalciferol) [125].  
Vitamin D (D3 or D2) is transported in chylomicrons through the lymphatics to the circulation. 
There it is either stored in fat cells or binds to the vitamin-D-binding protein and is delivered to 
the liver, where it undergoes conversion from the vitamin-D-25-hydroxylase to 25-
hydroxyvitamin D [25(OH)D]. Several cytochrome P450 (CYP) isoforms have been proposed 
to perform this hydroxylation step (CYP27A1, CYP2R1, CYP3A4 and CYP2J3). Finally, the 
25-hydroxyvitamin D-1a-hydroxylase (CYP27B1) in the kidneys converts it to its biologically 
active form 1,25-dihydroxyvitamin D [1,25(OH)2D or 1α,25(OH)2-Cholecalciferol or Calcitriol] 
[12].  
2.2.2 Role of Vitamin D in Humans 
Vitamin D plays a central role to calcium and phosphorus homeostasis. Its active form, 1,25-
dihydroxyvitamin D, increases the absorption of renal and intestinal calcium and phosphorus 
absorption. Production of 1,25(OH)2D is stimulated by low serum phosphate levels and by 
parathyroid hormone, which in turn is secreted in response to low serum calcium levels. 
Fibroblast growth factor 23 (FGF-23) suppresses 1,25(OH)2D synthesis. Also, the active 
1,25(OH)2D form affects the parathyroid glands directly as a negative feedback mechanism, 
reducing parathyroid hormone synthesis itself [89]. 
Active vitamin D enters the cell and forms a heterodimer with the vitamin D receptor, which in 
turn binds to the retinoid receptor. This complex activates vitamin D responsive genes leading 
to transcription and translation, such as that of osteocalcin or calcium binding protein in the 
intestinal mucosa. Calcium binding protein in turn regulates the active transport of calcium 
through the intestinal cells [89]. By activation of the vitamin D receptor, 1,25(OH)2D causes in 
osteoblasts an increase of the receptor activator of nuclear factor-κB ligand (RANKL). This 




osteoclasts. Mature osteoclasts remove calcium and phosphorus from the bone, causing an 
increase of calcium and phosphorus serum levels. 
2.2.3 Vitamin D Deficiency 
There is no consensus on the optimal vitamin D levels in serum. A widely accepted cut off for 
“vitamin D deficiency” is 20 ng per milliliter. Serum 25-hydroxyvitamin D concentrations are 
related inversely to parathyroid hormone concentrations, which begin to rise when 25-(OH)D 
concentration falls below 30-40 ng/ml[31]. Intestinal calcium transport also increases by 20 % 
when 25-(OH)D levels rise from 20 ng/ml to 32 ng/ml. This has led to the introduction of the 
term “vitamin D insufficiency” referring to serum vitamin D levels of 21-29 ng/ml. Above 150 
ng/ml, on the other hand, vitamin D intoxication may occur. Consequently, 25-(OH)D serum 
levels between 30 and 100 ng/ml are considered as normal. 
Low concentrations of vitamin D lead to an impaired calcium absorption. Low calcium levels 
induce a compensatory rise in parathyroid hormone (PTH), which results in excessive bone 
resorption and osteoporosis.  
2.2.4 Skeletal Effects of Vitamin D Supplementation 
While the data has been inconsistent, meta-analyses of randomized-controlled trials of vitamin 
D and calcium supplementation have shown a reduction in fracture risk and a modest increase 
in bone density, especially in patient subgroups with good compliance to the treatment [19,67].  
A relationship between 25-(OH)D serum levels and fracture risk has been established for levels 
below 20 ng/ml. A prospective trial with older women has shown the highest benefit at levels 
of about 25 ng/ml [125]. 
2.2.5 Non-Skeletal Effects of Vitamin D Supplementation 
In observational studies low levels of 25-(OH)D have repeatedly been associated with 
increased risk of diabetes mellitus, cancer, autoimmune as well as cardiovascular disease 
[125]. Prospective trials and meta-analyses, however, have failed so far to provide solid data 
of a reversal of these risks under vitamin D supplementation.  
Specifically, vitamin D supplementation has not been associated with a lower risk of 
cardiovascular events or all-cause mortality [67]. Concerning muscle strength, a benefit in 
supplementation has been shown in systematic reviews of randomized trials in older 




2.2.6 Vitamin D and Cancer 
Data on cancer incidence has been contradictory. Whereas some suggest an association 
between vitamin D deficiency and an increase in cancer incidence, in other trials higher vitamin 
D levels (≥ 40 versus 20-30 ng/ml) were associated with an elevated cancer risk [135,136]. 
In colon cancer, higher vitamin D levels were associated with an improvement in overall 
survival (OS) and progression-free survival (PFS) in a prospective trial [165]. A double-blind 
phase 2 randomized clinical trial of 139 patients with advanced or metastatic colorectal cancer 
receiving mFOLFOX6 plus bevacizumab and either high- or standard-dose vitamin D was able 
to demonstrate a non-significant increase in PFS with high dose vitamin D [106]. A Japanese 
single center, double-blind, placebo-controlled trial randomized 417 patients with digestive 
tract cancer to receive vitamin D (2000 IU/d) or placebo. Supplementation did not result in 
significant improvement in relapse-free survival at five years [147]. 
A recent post hoc analysis of the RICOVER trial of the German High Grade Lymphoma Study 
Group (DSHNHL) led to the important finding, that a sufficient supply of vitamin D positively 
influenced the prognosis of patients with DLBCL treated with chemotherapy combined with 
rituximab, but not of patients treated with chemotherapy alone. This effect in more pronounced 
in female compared to male patients [20]. Since ADCC is one of the major effector mechanisms 
of rituximab, a further study was conducted analyzing (among others) rituximab-mediated 
cellular cytotoxicity against a lymphoma cell line before and after vitamin D substitution. It could 
be shown that healthy subjects who achieved 25(OH)D serum levels of > 30 ng/mL had a 
significantly stronger ADCC. Again, ADCC enhancement was more pronounced in NK cells 
derived from female patients [105].  
2.2.7 Vitamin D and the Immune System 
Several epidemiological studies have linked vitamin D levels with the incidence of autoimmune 
diseases like diabetes mellitus type I, systemic lupus erythematosus, multiples sclerosis, 
inflammatory bowel disease and rheumatoid arthritis. Vitamin D receptor(VDR) is expressed 
in almost all immune cells, including activated CD4+ and CD8+ T cells, B cells, NK cells, 
neutrophils, and antigen-presenting cells such as macrophages and DCs [12],[162]. 
Furthermore, most immune cells express CYP27B1 including macrophages, B-, T-
lymphocytes and DCs which also express CYP2R1. It has been subsequently suggested that 
these cells can convert 25(OH)D3 into bioactive 1,25(OH)2D3.  
2.2.7.1 Innate Immunity 
1,25(OH)2D has been shown to enhance the antimicrobial properties of immune cells such as 
monocytes and macrophages. Vitamin D particularly affects the differentiation of monocytes 




cell-typical surface molecules MHC-II, CD40, CD80, and CD86 are less well expressed under 
1,25(OH)2D and production of IL-1, IL-6, TNF-α, IL-8, and IL-12 is reduced [12].  
Vitamin D dependent antimicrobial activity via cathelicidin antimicrobial peptide (CAMP) has 
been confirmed in monocytes/macrophages against Mycobacterium tuberculosis in a TLR-
dependent manner [90]. More recently, macrophage activity against high-grade B cell 
lymphoma cells has also been shown to be vitamin D dependent [24]. The mechanism 
underlying this pathway seems to be the upregulation of the genes of cathelicidin hCAP-18, 
defensing b2 and NOD2 in monocytes, macrophages as well as in neutrophils and other 
myeloid cells. Exposure to vitamin D also induces downregulation of TLR2 and TLR4 on 
monocytes, which has been suggested to be a negative feedback mechanism to prevent 
excessive TLR activation and inflammation [12]. 
2.2.7.2 Adaptive Immunity  
Within the acquired immune system, 1,25-(OH)2D inhibits dendritic cell maturation and thus 
reduces the potential of these cells for activation of and antigen presentation to their 
corresponding target cells. DCs treated with 1,25-(OH)2D have a reduced capacity to trigger 
T-cell proliferation and alter T-cell responses. Typical surface markers of DCs, such as MHC-
class II and co-stimulatory molecules like CD40, CD80 and CD86 have been shown to be 
downregulated after activation of the vitamin D receptor. Furthermore, vitamin D regulates 
cytokine production, inhibiting the production of IL-12 and IL-23 while stimulated the IL-10 and 
CCL22 excretion. 
VDR expression is increased in T cells in their activated state. 1,25(OH)2D exerts a direct 
effect on the cytokine profiles of T cells. It causes reduced secretion of both inflammatory Th1-
cytokines such as IL-2 and IFN-γ as well as Th17-derived cytokines IL-17 and IL-21. 
B cells are also directly affected by vitamin D. 1,25-(OH)2D inhibits B cell proliferation, 
differentiation to plasma-cells, immunoglobulin secretion, memory B cell generation and 
induces B cell apoptosis [12]. 
2.2.8 Vitamin D and Natural Killer Cells 
In healthy elderly subjects, the NK-cell number and/or cytolytic activity has been positively 
associated with serum levels of vitamin D [98]. Recently, 25-OH-D3 substitution in deficient 
individuals has been shown to increase rituximab- as well as obinutuzumab-mediated NK-cell 
cytotoxicity in vitro.  Maximum NK-cell activity was observed at 65 ng/ml 25-OH-D3, which 
means that supplementation to lower levels would result in the failure of interventions with 
vitamin D [105]. Other studies have also shown increased NK-cell cytotoxicity with calcitriol 




not yet been possible to show a molecular relationship between vitamin D supply and NK-cell 
mediated ADCC.  
2.3 AIMS OF THIS THESIS 
So far we have seen that vitamin D deficiency correlates with worse survival in patients with 
DLBCL treated with rituximab-chemotherapy [20] and that NK-mediated ADCC in the presence 
of rituximab is enhanced after in vivo vitamin D supplementation against lymphoma cell lines 
[105]. Furthermore, these effects are more pronounced in female subjects. This implies a direct 
effect of vitamin D on NK cells and suggests that this may be, at least to some extent, a sex-
specific effect. This study aims primarily to unveil the molecular mechanisms through which 
vitamin D supplementation enhances NK-cell mediated ADCC. Secondary analyses will 
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3 MATERIALS AND METHODS 
3.1  STUDY DESIGN   
3.1.1 Inclusion and Exclusion Criteria 
We recruited eight otherwise healthy volunteers with 25(OH)D serum levels below 20 ng/ml. 
Other inclusion criteria were a minimum age of 30 years and a written informed consent to the 
planned procedure including possible side effects that may result from taking vitamin D 
supplementation. Exclusion criteria were lack of consent, the presence of hematological 
diseases and ongoing therapy with immune-modulating or -suppressive drugs. In particular, 
the intake of glucocorticoids, chemotherapeutics or biologicals was not compatible with 
inclusion in the study. 
3.1.2 Data Handling and Ethical Aspects 
The data of the volunteers were encrypted. Each participant was assigned an internal 
identification number, which could be used to send pseudonymised blood samples to the 
Institute of Clinical Chemistry and Laboratory Medicine at the Saarland University Medical 
Center without risking invasion of privacy. The study was approved by the Ethics Commission 
of the Saarland Medical Association (identification number 178/17) and carried out in 
accordance with the Declaration of Helsinki. 
3.1.3 Vitamin D Supplementation 
Each individual received vitamin D supplementation a target 25(OH)D serum level of 65 ng/ml. 
For this a modified formula according the one proposed by van Groningen et al. was used 
[148]. Cholecalciferol (I.U.) =Δ 25-OH-D3 (ng/ml) × body weight (kg) × 200 (with “Δ 25-OH-D3” 
meaning the difference between the current and the target 25-OH-D3 serum level). Applying 
this formula, the pre-defined serum level was achieved within a narrow margin in nearly all 
individuals. The cholecalciferol product Dekristol® 20.000 I. U. (mibe GmbH Arzneimittel, 
Brehna, Germany) was used.  
After vitamin D supplementation, serum levels of calcium and phosphate were determined in 
order to avoid vitamin D intoxication and take appropriate countermeasures if necessary. In all 
subjects, however, the calcium and phosphate levels remained within the normal range. 
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3.1.4 Sample Labeling  
Samples obtained at the stage of vitamin D deficiency were assigned the suffix “a”. Samples 
obtained after vitamin D supplementation received the suffix “b”. Table 2 provides the 
participant list and the label of each sample.  





After vitamin D 
supplementation 
70 70a 70b 
71 71a 71b 
72 72a 72b 
73 73a 73b 
74 74a 74b 
75 75a 75b 
92 92a 92b 
99 99a 99b 
3.1.5 Participant Characteristics and Vitamin D Levels 
A previous study done by our group had shown that NK cell cytotoxicity was highest at 
approximately 65 ng/ml vitamin D [105]. We collected the samples from these same eight 
healthy volunteers at the at vitamin D deficient state and after vitamin D supplementation to 
approximately 65 ng/ml. Their characteristics and vitamin D levels are presented in Table 3. 







Vitamin D levels 
in deficient status 
(ng/ml) 
Vitamin D levels after 
supplementation 
(ng/ml) 
70 male 78 5.9 64.3 
71 female 71 23 68.2 
72 male 57 15.7 62.6 
73 female 78 4.6 68.8 
74 male 79 6.1 72.8 
75 female 79 9.7 68.5 
92 male 86 10.3 58.2 
99 female 42 8.8 61.5 
Mean - 71.3 10.5 65.6 
Materials and Methods 
17 
 
3.2  MATERIALS  
3.2.1 Chemicals, Reagents, Buffers, Mediums and Solutions 
Table 4: Chemicals, reagents, buffers, mediums and solutions used in the study 
Name Manufacturer, Article number 
Dekristol® 20.000 I. U. mibe GmbH Arzneimittel 
Brehna, Germany 
Phosphate-buffered saline (PBS) Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Article number: D8537-1L 
Ethylenediaminetetraacetic acid 
(EDTA, 0,5 M) 
Life Technologies Europe BV 
Bleiswijk, Niederlande 
Article number:15575020 
Fetal calf serum (FCS) Sigma Aldrich Chemie GmbH 
Munich, Germany 
Article number: F0804-500ML 
L-Glutamin (200 mM) Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Article number: G7513-100ML 
Penicillin-Streptomycin (10.000 U/ml 
Penicillin, 10 mg/ml Streptomycin) 
Sigma Aldrich Chemie GmbH 
Munich, Germany 
Article number: P0781-100ML 
Pancoll human, Density: 1.077 g/ml PAN Biotech GmbH 
Aidenbach, Germany 
Article number: P04-60500 
Deionised water (Aqua) Braun GmbH 
Kronberg im Taunus, Deutschland 
Article number: 113328002 
Ethanol, absolute for analysis 
EMSURE® 
ACS, ISO, Reag. Ph Eur 
Merck KGeA 
Darmstadt, Germany 
Article number: K49631383743 
Agarose NEEO Ultra-quality Carl Roth GmbH + Co. KG   
Karlsruhe, Germany 
Article number: 2267.4 
Sodium-Acetate (C2H3NaO2) Merck KGeA 
Darmstadt, Germany 
Article number: TA555568 920 / 1062681000 
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Sodium Hydroxide (NaOH) Merck KGeA 
Darmstadt, Germany 
Article number: 1064691000 
3-(N-morpholino)propanesulfonic 
acid (MOPS) Buffer 
Calbiochem 
San Diego, USA 
Article number: B32914 
Diethyl Pyrocarbonate (DEPC) SERVA Electrophoresis GmbH 
Heidelberg, Germany 
Article number: 23020 
Ethidium Bromide Solution 1% Carl Roth GmbH + Co. KG   
Karlsruhe, Germany 
Article number: 2218.1 
Cell wash BD GmbH (Becton, Dickinson and Company) 
Heidelberg, Germany 
Article number:349524 
MACS®-Buffer 0,5 % FCS 
2 mM EDTA 
ad 15 ml PBS 
MACS® NK Cell Isolation Kit, human  Miltenyi Biotec GmbH 
Bergisch-Gladbach, Germany 
Article number:130-092-657 
miRNeasy®Mini Kit Qiagen N.V. 
Venlo, Netherlands 
Article number: 217004 
SuperScript™ III Reverse 
Transcriptase kit 
Thermo Fisher Scientific,  
Waltham, Massachusetts, USA 
Article number: 18080093 
LightCycler® FastStart DNA Master 
SYBR Green I 
Hoffmann-La Roche AG 
Basel, Schwitzerland 
Article number: 12239264001 
RNA Gel Loading Dye (2X) Thermo Fisher Scientific,  
Waltham, Massachusetts, USA 
Article number: R0641 
RiboRuler High Range RNA Ladder Thermo Fisher Scientific,  
Waltham, Massachusetts, USA 
Article number: SM1821 
AffymetriGeneChip WT PLUS 
Reagent Kit 
Affymetrix, Inc.,  
Santa Clara, USA 
Article number: 902281 
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GeneChip™ Human Gene 2.1 ST 
Array Plate 
Thermo Fisher Scientific,  
Waltham, Massachusetts, USA 
Article number: 902136 
The article number is only given if the item in question is not part of a laboratory’s standard 
equipment. 
3.2.2 Antibodies, Enzymes, Primers 
Table 5: Antibodies, enzymes, primers used in the study 
Name Manufacturer, Article number 
Anti CD16-FITC BD GmbH (Becton, Dickinson and Company) 
Heidelberg, Germany 
Article number: 656146 
Anti CD56-PE BD GmbH (Becton, Dickinson and Company) 
Heidelberg, Germany 
Article number: 345812 
Primer for cDNA Synthesis  
(oligo-p(dt)15) 
Hoffmann-La Roche AG 
Basel, Schwitzerland  
Article number: 10814270001 
Primer "random" Hoffmann-La Roche AG 
Basel, Schwitzerland  
Article number: 11034731001 
CleanAmp™ dNTP Merck KGeA 
Darmstadt, Germany 
Article number: DNTPCA10-1KT 
3.2.3 Consumables 
Table 6: Consumables used in the study 
Name Manufacturer, Article number 
Centrifuge tube 15 ml Sarstedt AG & Co KG 
Nümbrecht, Germany Centrifuge tube 50 ml 
Reaction tube 0,5 ml 
Reaction tube 1,5 ml  
Reaction tube 2 ml  
Various pipette tips 
Serological pipettes 5ml 
Serological pipettes 25ml 
Materials and Methods 
20 
 
Serological pipettes 10ml Corning GmbH 
Kaiserslautern, Germany 
RNase-free Microfuge Tubes, 2.0 ml Thermo Fisher Scientific,  
Waltham, Massachusetts, USA 
Article number: AM12425 
RNase-free Microfuge Tubes, 1.5 mL Thermo Fisher Scientific,  
Waltham, Massachusetts, USA 
Article number: AM12400 
RNase-free Microfuge Tubes, 0.5 mL Thermo Fisher Scientific,  
Waltham, Massachusetts, USA 
Article number: AM12300 
MACS® LS-Column Miltenyi Biotec GmbH 
Bergisch-Gladbach, Germany 
Article number: 130-042-401 
QIAshredder® Column Qiagen N.V. 
Venlo, Netherlands 
Article number: 79654 
Microseal 'B' PCR Plate Sealing Film, 
adhesive, optical 
Bio-Rad Laboratories, Inc. 
California, USA 
Article number: MSB1001 
Hard-Shell® 96-Well PCR Plates, low 
profile, thin wall, skirted, white/clear 
Bio-Rad Laboratories, Inc. 
California, USA 
Article number: HSP9601 
The article number is only given if the item in question is not part of a laboratory’s standard equipment. 
3.2.4 Equipment 
Table 7: Equipment used in the study 
Name Manufacturer, Article number 
Centrifuge 5810 R Eppendorf AG 
Hamburg, Germany Centrifuge 5415 D 
Pipette Research 1-10 µl 
Pipette Research® 10-100 µl 
Pipette Research® 100-1.000 µl 
Handdispenser Multipette® M4 
Biological Safety Cabinet HERAsafe™ 
HSP 18 
Life Technologies GmbH / Thermo Fisher 
Scientific 
Darmstadt, Germany 
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MACS® MidiMACS™ Separator Miltenyi Biotec GmbH 
Bergisch-Gladbach, Germany 
Article number: 130-042-302 
Flow cytometer FACSCalibur™ BD Biosciences GmbH 
Heidelberg, Germany 
Article number: 342975 
Vortex mixer Heidolph REAX top Heidolph Instruments GmbH & Co.KG 
Schwabach, Germany 
Mini-Sub DNA cellTM Electrophoresis 
Cell 
Bio-Rad Laboratories, Inc. 
California, USA 
UVP High-Performance UV 
Transilluminator TFS-20, 25 Watt, 254 
nm UV 
Thermo Fisher Scientific,  
Waltham, Massachusetts, USA 
Article number: P/N 95-0319-02 
NanoDrop 1000 Spectrophotometer Thermo Fisher Scientific,  
Waltham, Massachusetts, USA 




IKA® KS250 basic Shaker IKA-Werke 
Staufen im Breisgau, Germany 
Article number: 93-139-20 
CFX Connect™ Real-Time PCR 
Detection System 
Bio-Rad Laboratories, Inc. 
California, USA 
Article number: 788BR03770 
The article number is only given if the item in question is not part of a laboratory’s standard equipment. 
3.3  METHODS 
3.3.1 Cell Counting 
The experimental setup required precise knowledge of the number of cells in a suspension. 
Since the exact volume of the cell suspension must be known in order to calculate the cell 
number, it was first determined using a suitable graduated pipette. 5 µl were taken from the 
cell suspension and diluted with PBS to a total volume of 50 µl. This diluted suspension was 
mixed with trypan blue in a ratio of 1:1. Trypan blue is a staining agent commonly used in cell 
biology to identify dead cells, since it is exclusively absorbed by apoptotic and necrotic cells, 
while vital cells do not stain [137]. Therefore, it was easy to count selectively the vital unstained 
cells. The proportion of dead cells was always below 10 %. Counting itself was done according 
to the Neubauer method using a chamber slide with the same name. 
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3.3.2 Isolation of PBMC 
To isolate the NK cells, approx. 50 ml of whole blood were taken from the respective volunteer 
on the day of the ADCC test in commercial blood collection tubes with the anticoagulant EDTA. 
To isolate the NK-cell fraction, the peripheral blood mononuclear cells (PBMC) were first 
separated by density gradient centrifugation. PBMC are a mixture of T- and B-lymphocytes, 
monocytes, DCs, and NK cells. The relative proportion of individual leukocyte populations 
varies inter- and intraindividually. Granulocytes (also: polymorphonuclear cells; PMN) do not 
belong to the PBMC. 
PancollTM, a synthetic sucrose-epichlorohydrin copolymer, was used to build up the density 
gradient required to isolate the PBMC. With a density of 1.077 g/ml, PancollTM separates the 
PBMC fraction during centrifugation from the erythrocytes and granulocytes, the two remaining 
cell populations of the peripheral blood, due to their higher density towards the centripetal. Due 
to its slightly cytotoxic effect, PancollTM has to be rinsed out immediately after isolation of the 
PBMC[23]. 
For density gradient centrifugation, 4 ml PancollTM were placed in a 15 ml centrifuge tube. The 
approximately 50 ml of EDTA whole blood were diluted with about 16 ml PBS to be distributed 
to six centrifuge tubes. To this end, the 4 ml PancollTM were carefully coated with 11 ml of the 
EDTA whole blood/PBS suspension and centrifuged for 30 minutes at room temperature and 
500 g.  
After centrifugation, the phase containing the PBMC was harvested from all tubes and 
collected in a 50 ml centrifuge tube. Then the PBMC were washed twice with cold PBS and 
centrifuged in each case (10 min, 4 °C, 300 g). After centrifugation the supernatant was 
discarded, and the pellet was resuspended in fresh PBS. After the second washing, the pellet 
was resuspended in 7 ml PBS and the vital PBMC were counted. 
3.3.3 NK-Cell Enrichment by Magnetic Cell Sorting 
The second step, after the isolation of the PBMC, was the enrichment of the NK cells from the 
PBMC. This was done by means of magnetically activated cell sorting (MACSTM). In this 
process, the cell types which ought to be enriched or eliminated, were magnetically marked 
with cell-type-specific markers (mostly CD molecules). This was done with marker-specific 
antibodies, which are bead-coupled. In this case the non-NK cells were depleted from the 
PBMC. The different cell populations of the PBMC that are not NK cells, i.e. T cells, B cells 
and monocytes, as well as post-Pancoll cell type residues (granulocytes, erythroid cells, etc.) 
were labelled with an appropriate antibody cocktail. The bound antibodies were then coupled 
with magnetic beads via a biotin/anti-biotin bridge. This bead/antibody-cell suspension then 
was applied to an LS separation column that was positioned in a magnetic field. In the magnetic 
field, the labelled non-NK cells remained stuck, while the unlabeled NK cells passed through 
Materials and Methods 
23 
 
the column unhindered. The NK cells then were centrifuged, and the pellet was resuspended 
in medium. From this NK-cell suspension, both the sample to determine the cell count 
according to Neubauer and the sample for flow cytometric analysis of CD16/CD56 purity were 
taken. 
The NK Cell Isolation Kit, human from Miltenyi Biotec GmbH, was used for this purpose. The 
kit was used according to the protocol of the provider. Calculating the number of PBMC used, 
the capacity of the MACSTM column and the isolation strategy were considered. Due to the 
binding capacity of the LS-separation column of a maximum of 108 marked (non-NK) cells and 
the depletion strategy described above, a maximum of only 108 PBMC were used from each 
subject. These were centrifuged once more (10 minutes, 300 G, 4 °C), the liquid supernatant 
discarded and the PBMC pellet resuspended in 40 µl MACSTM buffer per 107 cells. Now 10 µl 
of the biotin antibody mixture per 107 cells were added to label the non-NK cells. This 
suspension was thoroughly mixed and incubated at 4 °C for 5 minutes. Then 30 µl MACSTM 
buffer and 20 µl MicroBeads were added to label the bound antibodies for MACS separation, 
again per 107 cells. After subsequent mixing and 10 minutes incubation at 4 °C, the PBMCs 
could be sorted. The cell suspension was placed in the MACSTM-LS column, which had 
meanwhile been equilibrated with 3 ml MACSTM buffer. After passing through this suspension, 
the column was rinsed twice with 3 ml MACSTM buffer. 
The LS column with the bound non-NK cells was discarded. The NK cells isolated in the run 
were centrifuged after sampling for flow cytometric quality control to remove the MACSTM buffer 
(300 G, 10 minutes, 4 °C). The cell pellet was incorporated in 500 µl ADCC medium (NK-cell 
stock suspension). The cells were then quantified. 
3.3.4 Flow Cytometry 
Approximately 90 % of the NK cells are to be assigned to subtype CD56dim/CD16high, which 
has pronounced cytotoxicity. CD16 refers to FcγIIIRa, which is an antibody receptor essential 
for ADCC. Instead, other subpopulations such as CD56bright/CD16dim show increased 
immunoregulatory functions such as the production of cytokines. They may also be precursors 
of CD16+ NK cells. However, since the aim of this work was to investigate the ability of NK 
cells to ADCC, the proportion of CD16+ cells, regardless of CD56 expression, was determined 
by fluorescence-activated flow cytometry. 
After MACSTM isolation, 80 µl of the NK cell stock suspension was removed and centrifuged in 
a reaction vessel (2 minutes, 400 G). The supernatant was discarded, and the cell pellet was 
resuspended in 50 µl PBS. This NK suspension was incubated for 15 minutes with 2.5 µl each 
of the two fluorescence-labeled antibodies CD16 FITC (CD16 fluorescein isothiocyanate) and 
CD56 PE (CD56 phycoerythrin). After renewed centrifugation (same parameters) to remove 
unbound antibodies, the CD16- and CD56-labelled NK cells were dissolved in 120 µl Cell 
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WashTM. The number of vital lymphocytes was counted according to Neubauer and the 
proportion of CD 16+ cells was determined by flow cytometry. With these two parameters the 
exact number of enriched NK cells was calculated. 
3.3.5 RNA Extraction 
After the ADCC assay, the remaining NK cells were stored in pellets at - 80 °C. The stored cell 
suspensions contained from 5 x 106 to 1 x 107 NK cells. Prior to storage cells culture medium 
was removed after centrifugation of the cell suspension for five minutes at 300 G. At the time 
of RNA extraction, the cell pellets were removed from storage and immediately processed. For 
RNA isolation, the miRNeasy Mini KitTM (Qiagen, Velno, Holland) was used, according to the 
included protocol. To perform cell disruption, after loosening the cell pellets by manual flicking 
of the tubes, 700 µl QIAzol Lysis ReagentTM was added and the mixture was mixed by pipeting 
and vortexing for a few seconds. The tubes were then left for five minutes on the benchtop at 
room temperature.  Homogenization was achieved with a QIAshredder spin columnTM (Qiagen) 
to avoid cross-contamination of samples. 700 µl of each lysate were added on the individual 
spin columns, which were each placed in 2 ml collection tubes. The tubes were centrifuged for 
two minutes at maximum speed. The spin columns were then disposed. After adding 140 µl of 
chloroform to the collection tubes, the mixture was vortexed for 15 s and the homogenates 
were left at room temperature for two minutes. Another centrifugation followed at 12,000 G at 
4°C for 15 minutes. Subsequently the upper aqueous phases were transferred to new 
collection tubes. 525 µl of 100 % ethanol were added to each sample followed by thorough 
mixing with the pipette. 700 µl of this sample were transferred into an RNeasyTM spin column 
in a 2 ml collection tube. A short centrifugation of 15 s at 8,000 G followed. The process was 
repeated with the rest of the sample, the flow-through was discarded. 700 µl of buffer RWTTM 
was added to the spin column and after centrifugation for 15 s at 8,000 G the flow-through was 
discarded. The same centrifugation und discarding of flow-through was repeated after adding 
500 µl of RPE bufferTM. Thereafter, the spin column again was transferred into a new 2 ml 
collection and centrifuged at full speed for one minute, to avoid carry over of flow-through 
remains into the RNA elution phase. For the final step, the spin columns were transferred one 
last time to new 1.5 ml collection tubes. 30 µl of RNase-free water were pipetted onto each 
sample, followed by centrifugation at 8,000 G for 1 minute. A relatively small sample volume 
(30µl) was chosen on purpose in favour of a higher sample RNA concentration. 
3.3.6 Spectrophotometry  
For spectrometry, the NanoDrop 1000 Spectrophotometer was used. Prior to each 
measurement 2 µl RNase-free water aliquots were loaded to clean measurement surfaces. 
For each sample 2 µl were loaded onto the measurement pedestal.  
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3.3.7 RNA Electrophoresis  
RNA is particularly susceptible to degradation. Therefore, all used solutions were prepared 
with RNAse free, deionized water, which was prepared using DEPC. For this 2 ml DEPC was 
added to one liter deionized water. After mild shaking, the solution was shaken at 37 °C 
overnight. The remaining DEPC was removed by autoclaving.  
To create the gel for RNA electrophoresis, an appropriate 3-(N-morpholino) propanesulfonic 
acid (MOPS) 20x buffer solution was prepared. For this purpose, 83.72 g of MOPS and 8.23 g 
of sodium acetate were added to 700ml of DEPC-treated water, followed by stirring until 
complete dissolution. 7.4 g EDTA were added to the mixture as well as NaOH until a pH of 7 
was achieved. Finally, DEPC-treated water was added up to 1000 ml and the flask was 
covered with aluminum foil.  
For the purpose of our experiment, a 150 ml agarose gel was cast. Initially 1,5 g of the agarose 
powder was mixed with 142.5 ml of DEPC-treated water and was left to boil in the microwave 
for three minutes. The solution was cooled down on a shaker for ten minutes, after which 75 
μl of ethidium bromide and 7.5 ml 20x MOPS buffer were added. The gel was casted under 
the hood in sterile conditions and subsequently stored at 4 °C. 
As running buffer for the electrophoresis 1x MOPS solution was used.  To create 250 ml of 1x 
MOPS solution 12.5 ml of the 20x MOPS solution were diluted with 237.5 ml DEPC-treated 
water.   
The sample preparation was done in a prompt matter and RNA samples were kept in ice. In a 
new, 0.5 ml RNase-free tube, 5 µl of RNA loading dye and 5 µl of RNA-free water as well as 
100 ng of sample RNA were added. The tubes were heated up to 65 °C for five minutes and 
loaded onto the gel. The mixture was run with 80 Watt for approximately 30 minutes.  Finally, 
gels were read out on an UV transluminator. 
3.3.8 Microarray Assay 
For RNA expression analysis the GeneChip™ Human Gene 2.1 ST Array Plate was chosen. 
RNA coverage and technical information of the chosen microarray are demonstrated in Table 
8. Because of the broad coverage of the microarray, we refrained from testing for expression 
of receptors on the NK cell surface or measuring cytokine levels. We assumed that an 
increase/decrease in protein production must be reflected in the produced mRNA levels.  
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Table 8: Technical Information about the Human Gene 2.1 ST Array Plate 
Transcript Category Number covered 
Total RefSeq transcripts covered 40,716 
NM – RefSeq coding transcript, well-established annotation 30,654 
NR – RefSeq non-coding transcript, well established annotation 5,638 
XM – RefSeq coding transcript, provisional annotation 996 
XR – RefSeq non-coding transcript, provisional annotation 3,428 
lncRNA transcripts 11,086 
RefSeq (Entrez) gene count  24,838 
The microarray contained both non-coding and coding transcripts. Furthermore, of the coding 
transcripts, not all have well established annotations. Referring to microarray results, we use 
the term “transcript” to include all the above. By using the term “gene”, we refer to probes 
containing DNA sequences encodings proteins or RNA with a well-established annotation. 
Sample preparation and microarray hybridization was carried out with the AffymetriGeneChip 
WT PLUS Reagent Kit at an Affymetrix Service Provider and Core Facility, “KFB - Center of 
Excellence for Fluorescent Bioanalytics” (Regensburg, Germany; www.kfb-regensburg.de) as 
described in the user Manual. In short: for each sample, double-stranded cDNA was generated 
from 200 ng of total RNA. 12 µg of subsequently synthesized cRNA was purified and reverse 
transcribed into sense-strand (ss) cDNA. Incorporation of unnatural dUTP residues also took 
place at this stage. Purified ss cDNA was fragmented using a combination of uracil DNA 
glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 1) followed by a terminal 
labeling with biotin. 3,8 µg of fragmented and labeled ss cDNA were hybridized to Affymetrix 
Human Gene 2.1 ST Array Plates. For hybridization, washing, staining and scanning an 
AffymetriGeneTitan system, controlled by the AffymetriGeneChip Command Console software 
v4.2, was used. 
3.3.9 Microarray Quality Control 
Different signal and quality metrics were calculated to assure data quality and to identify outlier 
samples. First, the signal strengths across all arrays were displayed in a histogram (Figure 1). 
Prior to data normalization, a Box Plot for Log Probe Cell Intensity (Figure 2) and a Box Plot 
for Relative Log Probe Cell Intensity (Figure 3) were created. This allowed a comparison of 
the distribution of intensities on each array with the mean value of the probe intensity of the 
whole group. After normalization and log2-transformation, the logarithmic values of the signal 
strength of the expression were displayed in the form of a boxplot, both absolute (Log 
Expression Signal (Figure 4)) and relative (Relative Log Expression Signal (Figure 5)). 




Figure 1: Distribution of signal strengths 
Histogram of the signal strength for each array. The signal strengths of the individual arrays 




Figure 2: Log probe cell intensity 
Distribution of the log signal intensities for each sample. Because the intensities were prior to 
normalization, some differences in the distributions were to be expected. No concerning outliers could 
be identified.  




Figure 3: Relative log probe cell intensity 
The relative log probe cell intensity summarizes the distribution of the ratio of signal for each probe set 
to the median probe set signal across all the selected arrays. Therefore, the plot compares the 
distribution of probe set signal values on each array to the median array for the group. Again, the data 
were homogeneous enough and no outliers could be identified. 
 
 
Figure 4: Log expression signal 
This plot displays the results of log probe cell intensity (Fig. 2) after normalization. The normalized data 
were completely homogeneous and confirmed the reliability of the results obtained. 
 




Figure 5: Relative log expression signal 
This plot summarizes the ratio distribution of the signal for each probe set to the median probe set signal 
across all arrays. It allows the comparison of the distribution of probe set signal values on each array to 
the median array for the group, thus enabling the identification of outliers. Again, after normalization, the 
relative log expression signals were even more homogeneous. 
Furthermore, to look at the relationship between the variables in our samples and to identify 
outliers, two standard statistical methods of linear correlation were used: Pearson’s and 
Spearman Rank Correlation. The correlation values were displayed as heatmaps, in order to 
simplify the interpretation of the data (Figure 6 and Figure 7). No outliers were identified with 
this method. 




Figure 6: Pearson's correlation (signal) 
The Pearson’s correlation coefficient (r2) value was used to evaluate signal concordance between two 
arrays. This heap map provides a pairwise comparison of signal values from all arrays. r2 values have 
been converted into a pseudocolor scale. Darker red indicates higher concordance between the two 
signals, deeper blue means weaker concordance. No outliers could be identified. 
 
Figure 7: Spearman rank correlation (signal) 
The Spearman’s correlation is another method to evaluate signal concordance between two arrays. This 
heap map provides a pairwise comparison of signal values from all arrays, after the r2 values have been 
converted into a pseudocolor scale. Darker red indicates higher concordance between the two signals, 
deeper blue means weaker concordance. No outliers could be identified. 
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Other metrics were calculated to assure data quality. The most important ones are listed here 
and in Table 9 and Table 10. 
Pm mean: The mean of the raw intensity for all probe sets on the array prior to any intensity 
transformation. This metric can be used to detect bright or dim arrays.  
Bgrd mean: The mean of the raw intensity for the probes used to calculate background prior 
to any intensity transformations. 
All probesets mad residual mean: The mean of the absolute deviation (MAD) of the residuals 
from the median imposed by RMA. The difference between the actual value and the predicted 
value is called the residual. One can use this metric to identify arrays that have a large number 
of probes that are behaving differently than predicted by the model. An unusually high value 
may be a sign of a problematic sample. 
All probesets rle mean: The mean absolute relative log expression (RLE). The signal of each 
probe set is compared to the median signal value of this probe set in the study. The metric is 
the mean of these differences from all the probe sets. Unusually high values indicate that the 
signals on the array are different from others in the study, i.e., big values are bad. This metric 
is most useful for studies with similar sample types to detect outlier arrays. For a set of different 
tissues, for example, this metric is less useful. 
Polya spike-AFFX-…: Each eukaryotic GeneChip probe array contains probe sets from 
several B. subtilis genes (lys, phe, thr, and dap) that are absent in eukaryotic samples. These 
exogenous Poly-A RNA controls are spiked into the RNA sample at staggered concentrations, 
carried through the sample preparation process, and evaluated like the internal control genes. 
Increasing signal values in the order of lys, phe, thr, dap, indicate that the entire target labeling 
process was successful. 
While the Phe-Poly-A spike is a little lower in that the Lys-Poly-A spike in probes 72a, 73b and 
99a, the consequent spikes show regular progression. Small variations are a common 
observation in such experiments. Most importantly the Pearson and Spearman rank correlation 
clearly demonstrated that no outliers occurred, and the entire process was successful for all 
probes. 
Table 9: Quality control metrics 1 






70a 155.140656 46.551620 0.473750 0.232106 
70b 167.635880 48.638466 0.460750 0.215163 
71a 144.445374 41.769939 0.485249 0.235982 
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71b 129.346237 42.630573 0.485151 0.219818 
72a 137.584396 43.701363 0.513390 0.268264 
72b 150.244781 44.657310 0.467746 0.220739 
73a 131.385452 41.583717 0.466700 0.219056 
73b 145.320129 42.438477 0.478096 0.218702 
74a 142.617142 43.329399 0.475219 0.226132 
74b 158.431885 47.384987 0.475677 0.249287 
75a 118.250381 38.702301 0.489690 0.246375 
75b 127.325378 44.568146 0.505307 0.273880 
92a 149.966461 44.170410 0.457799 0.208877 
92b 110.753960 44.606228 0.549525 0.313621 
99a 143.950562 41.315315 0.482520 0.270620 
99b 141.638412 41.163925 0.498369 0.278563 
Abbreviations: Pm: Probe mean intensity; Bgrd: Background; mad: mean of the absolute deviation; rle: 
Relative log expression 
 














70a 7.190930 7.538183 8.119799 10.079699 
70b 7.094028 7.366222 7.724324 9.986629 
71a 6.796246 7.054669 7.426122 9.831928 
71b 7.228066 7.284276 7.874607 9.973407 
72a 6.865479 6.745480 7.790881 9.884852 
72b 7.073507 7.288373 7.646286 9.915456 
73a 7.314280 7.389640 8.019044 9.997330 
73b 7.068339 6.954660 7.894888 10.056053 
74a 6.889834 7.126411 7.611820 9.936298 
74b 6.775320 6.954896 7.520261 9.640957 
75a 6.996794 7.371268 7.693502 10.129491 
75b 7.435799 7.901404 7.965506 10.424582 
92a 6.842246 6.876032 7.394284 9.674782 
92b 7.521118 7.728622 8.210540 10.487738 
99a 6.721220 6.647304 7.193521 9.733693 
99b 7.946365 8.051426 8.522511 10.631655 
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3.3.10 Quantitative Real Time Polymerase Chain Reaction Validation 
Validation of the results of the microarray data was performed for a selected number of genes 
by quantitative Real Time Polymerase Chain Reaction (qRT-PCR). After acquisition of the 
microarray expression data, we searched for genes with significant, preferably variable 
expression across different samples and a housekeeping gene as control. Another 
requirement was the availability of a suitable primer for each gene. Two genes were chosen 
with strong differential expression before and after vitamin D supplementation: allograft 
inflammatory factor 1 (AIF1) and C-type lectin domain family 7, member A (CLEC7A). One 
housekeeping gene was chosen to act as a control: ubiquitin conjugating enzyme E2D 2 
(UBE2D2). For these three genes suitable primers were selected and synthesized (Sigma-
Aldrich, Darmstadt, Germany) (Table 11). We then proceeded to reverse transcription, cDNA 
synthesis and RT-PCR.  





Forward Primer Reverse Primer 
NM001623 AIF1 GCTATGAGCCAAACCAGGGA CCAGTTTGGAGGGCAGATCC 
NM022570 CLEC7A GCTGGCAACTGGGCTCTAAT AGGGCACACTACACAGTTGG 
NM003339 UBE2D2 ATCACAGTGGTCTCCAGCAC TCCCGAGCTATTCTGTTGTACTTTT 
The cDNA synthesis was done with the SuperScript™ III Reverse Transcriptase kit, according 
to the accompanying protocol. Firstly, 0.5 μl of oligo(dT)15 (50 µM), 1 ul of random primers, 1 
µl of dNTP mix (10 mM) and 200 ng of RNA were added in a RNase-free microcentrifuge tube. 
The total volume depended on the concentration of the RNA of the according sample. The 
micro centrifuge tube was then filled with sterile, distilled water up to 14 µl volume. The mixture 
was heated up to 65 °C for 5 minutes and subsequently incubated for 2 minutes on ice. 
Following a brief centrifugation to collect the contents of the tube, another 4 µl 5x First-Strand 
BufferTM, 1 µl of 0.1 M DTT and 1 µl of SuperScript™ III RT (200 units/µl) were added to the 
mixture, followed by thorough mixing. Finally, the mixture was incubated at 55 °C for 45 
minutes, followed by renewed heating to 70 °C to inactivate the reaction.  
The reaction mix for the RT-PCR was performed with the LightCycler®FastStart DNA Master 
SYBR Green I according to the accompanying protocol. A 10 µM concentration solution was 
prepared for each primer. 2 µl of this primer solution ware added to 2 µl LightCycler®FastStart 
DNA Master SYBR Green I, 0.4 µl of MgCl2 (25 µM) and 13.6 µl of PCR grade water to a total 
volume of 18 µl in a 1.5 ml reaction tube on ice. The mixture was mixed gently through pipetting 
and subsequently placed in a 96 well plate. Finally, 2 µl of cDNA template were added for each 
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sample. Each well was sealed with an adhesive sealing film. We conducted two PCR for each 
of the different genes/samples and a negative control PCR.  
Parameters for qRT-PCR are displayed in Table 12 and Table 13:  
Table 12: Parameters for PCR 








n/a 1  95°C 10 min none 
Amplification 
Quantification 45 
Denaturation 95 °C 10 s none 
Annealing s. Table 13 10 s none 
Extension 72 °C 30 s single 
Melting Curve 
Melting Curves 1 
Denaturation 95 °C 0 s none 
Annealing 65 °C 15 s none 
Extension 95 °C 0 s continuous 
Cooling 
n/a 1  40 °C 30 s none 
Abbreviations: n/a: not applicable. 




AIF1 66 °C 
CLEC7A 66 °C 
UBE2D2 66 °C 
The individual annealing temperatures of the qRT-PCR are summarized in Table 13. The cycle 
threshold (Ct) values represent the mean of the two results for each gene/sample. Each result 
was normalized by subtracting the Ct value of the housekeeping gene from the corresponding 
Ct value of each gene, thus acquiring the ΔCt value. Next, the ΔΔCt (a-b) value after vitamin 
D substitution was calculated by subtracting the ΔCt value after vitamin D substitution (Xb) 
from the ΔCt value before vitamin D substitution (Xa) for each subject.  
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3.4 STATISTICAL ANALYSIS 
3.4.1 Data Analysis Strategy 
Our data analysis strategy was divided into four levels. Firstly, we looked for statistically 
significant differentially expressed genes (see 3.4.2 below). Secondly, we looked specifically 
at genes which are, according to current knowledge, involved in the induction of NK cell 
cytotoxicity. Our third analysis searched for upregulated or downregulated pathways which are 
part of the immune response in broader sense. Lastly, an unsupervised, explorative analysis 
searched for pathways which were statistically significant up- or downregulated after vitamin 
D3 supplementation without any further restrictions. 
3.4.2 Comparisons 
The primary comparison of this study is between the two vitamin D states:  
a = deficiency  
and  
b = supplementation/substitution (these two terms are considered equivalent in this thesis).  
Consequently, we defined two groups for the comparison: 
➢ All test subjects in the vitamin D deficient state: “deficiency” (samples labeled with the 
suffix “a”) 
➢ All test subjects after vitamin D substitution: “substitution” (samples labeled with the 
suffix “b”) 
 
However, considering that sex may also play a role, four more groups were defined based on 
both vitamin D serum levels and sex:  
1. Deficient female subjects: “female – deficiency” 
2. Deficient male subjects: “male – deficiency” 
3. Supplemented female subjects: “female – substitution”  
4. Supplemented male subjects: “male – substitution”  
 
Using these definitions following comparisons were performed:  
Primary Comparison: 
• Comparison I: “deficiency” versus “substitution”  
 
Secondary Comparisons: 
• Comparison II: “female” versus “male” 
• Comparison III: “female – deficiency” versus “female – substitution” 
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• Comparison IV: “male – deficiency” versus “male – substitution” 
• Comparison V: “female – deficiency” versus “male – deficiency” 
• Comparison VI: “female – substitution” versus “male – substitution” 
3.4.3 Differentially Expressed Genes 
Probe set signals were background corrected, normalized and log2-transformed using the 
Robust Multi-array Average (RMA) algorithm [46] with the AffymetriGeneChip Expression 
Console v1.4 Software. After exporting into Microsoft Excel comparison fold changes were 
calculated.  
3.4.3.1 Comparison I:  
The paired t-test statistic was used for the primary comparison between the (vitamin D) 
deficiency and (vitamin D) supplementation/substitution states. The software SPSS (IBM 
SPSS statistics, version 23) was used to perform a Kolmogorov-Smirnov test to check for 
normality in result distribution. The “R” software (R Foundation for Statistical Computing, 
version 3.6.3) with the “limma” package (Bioconductor, version 3.42.2) was used for gene 
expression analysis [121,130]. The RobiNA graphical interface (version 1.24) was used to 
access the R software [92,93]. The default settings were used. A p-value of < 0.01 was chosen 
for statistical significance. Multiple correction was performed with the Bonferroni method. 
3.4.3.2 Comparisons II-VI: 
For these comparisons, which include the four afore mentioned groups based on sex and 
vitamin D status another statistical method was required. 
The analysis of variance (ANOVA) is a group of statistical methods that is used to determine 
if there statistically significant differences between the means of three or more groups of data. 
Thus, it can be used as an alternative to the t-test statistic for comparisons II-VI. Using the 
Transcriptome Analysis Console (TAC) Software (Thermofisher Scientific, 4.0.2 Release) with 
the integrated “limma” package (see above), two-sided analysis of variance (ANOVA), 
hierarchical clustering as well as principal component analysis (PCA) were performed.  
PCA is the process of projecting a group of date in two- or three-dimensional space as vectors 
(principal components). The spatial relation of theses vectors to each other provides an 
overview of the relation of the data sets to each other. 
Lastly, clustering is the process of grouping similar entities together in an attempt to profile the 
attributes of different groups. It can be used to identify biological meaningful patterns of 
expression within the different groups, as has been demonstrated as early as 1998 [45]. 
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For the before mentioned comparisons a p < 0.01 (ANOVA test) and an increase or decrease 
in fold change by factor > 1.5 were selected as criteria of significance. Correction for multiple 
testing was performed with the false discovery rate (FDR) method with a q-value < 0.05 
considered as significant. 
3.4.4 Pathway Analysis 
For pathway analysis Gene Set Enrichment Analysis (GSEA) and the online software tool 
GeneTrail were used. We created two classes, the (vitamin D) deficient phenotype (suffix “a”) 
and the phenotype after vitamin D substitution/supplementation (suffix “b”). We used the 
default class metric, Signal2Noise, which is the difference of means scaled by the standard 
deviation, and the weighted (p = 2) enrichment statistic to generate a ranked gene list. For the 
second step, a predefined gene set is required, which includes biologically related genes (e.g. 
genes encoding products of the same pathway). GSEA determines then if the members of the 
predefined gene set are randomly distributed throughout the ranked gene list, or primarily 
found at the top or at the bottom of the list. Gene sets whose distribution lies closely to a 
particular phenotype (top or bottom of the list) are considered to be related to the specific 
phenotype. The extent of the correlation with a specific phenotype is measured with the 
enrichment score. A level of significance for the enrichment score was calculated additionally 
by using permutation of the gene sets (labels). This is the preferred method in studies with 
small number of samples for each phenotype. Only values < 0.05 were accepted as 
significance level (p) and False Discovery Rate (FDR), respectively. 
We took a three-step approach to analyze our data. Firstly, we separated 7.705 genes known 
to be involved in the NK cell-mediated immune response according to the Gene Ontology 
database, irrespective of their individual expression. This dataset was used separately for 
specific analysis of the NK cell-cytotoxicity pathway to increase sensitivity. Secondly, the 
complete data set was used in an unsupervised, exploratory analysis to screen for other 
dysregulated pathways involved in the immune response and vitamin D homeostasis. 
Predefined gene sets representing specific pathways or genes involved in the same process 
can be found in online databases. One of the most comprehensive databases is the Molecular 
Signature Database [88]. This database includes a selection of gene sets involving core 
biological functions (“Hallmark” gene sets) and also features gene sets from other databases 
like the Biocarta, Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) 
and Reactome databases. From this broad library we selected 89 gene sets as predefined 
gene sets in our analysis. Both analyses were performed using the GSEA Software, Version 
4.0.3, Broad Institute.  
Finally, using the online software tool GeneTrail, we performed a screening for dysregulated 
pathways in the Hallmark, BioCarta, GO - Biological Process, GO - Cellular Component, GO - 
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Molecular Function, KEGG, Reactome and WikiPathways databases. Again, weighted GSEA 
was used. Because this was a non-hypothesis driven test, we reduced the p-value for 

























Initially, qRT-PCR was performed for result validation as explained in detail above (3.3.10, 
page 33). Thereafter, differential gene expression analysis was done using t-test statistic for 
the primary comparison and two-way ANOVA for the secondary comparisons (s. 3.4.2 and 
3.4.3, page 35). Finally, we performed guided and unguided pathway analysis using the GSEA 
and GeneTrail software (s. 3.4.4, page 37). 
4.1 QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION 
VALIDATION 
qRT-PCR and fold change results obtained from the microarray are listed in Table 14 and 
Table 15 respectively. ΔΔCt (a-b) values as per PCR are presented in Table 16. 
Table 14: qRT-PCR results 
Sample 
UBC AIF1 CLEC7 
Ct Ct ΔCt ΔΔCt (a-b) Ct ΔCt ΔΔCt (a-b) 
70a 22.61 28.13 5.52 -2.85 36.08 13.46 -2.86 




71a 22.10 26.69 4.59 -6.67 35.24 13.14 -8.71 




72a 22.51 34.77 12.25 6.98 43.15 20.64 6.70 




73a 22.71 28.99 6.28 -0.71 37.62 14.91 0.55 




74a 22.06 31.00 8.94 -4.01 36.02 13.96 -5.32 




75a 22.36 25.28 2.93 -4.38 34.65 12.30 -7.64 




92a 22.39 31.13 8.75 3.17 40.76 18.38 2.94 




99a 22.04 26.03 4.00 -0.14 34.70 12.67 2.13 










Table 15: Fold change microarray signal values after vitamin D substitution 
Gene 
Subject 
70 71 72 73 74 75 92 99 
AIF1 -3.75 -7.01 6.54 -1.09 -1.54 -5.26 2.04 -2.25 
CLEC7A -7.75 -11.50 4.86 1.05 -1.24 -12.51 3.93 -3.13 
Table 16: qRT-PCR ΔΔCt (a-b) values after vitamin substitution 
Gene 
Subject 
70 71 72 73 74 75 92 99 
AIF1 -2.85 -6.67 6.98 -0.71 -4.01 -4.38 3.17 -0.14 
CLEC7A -2.86 -8.71 6.70 0.55 -5.32 -7.64 2.94 2.13 
A graphical representation of the data depicted in Table 15 and Table 16 are shown in Figure 
8 and Figure 9 respectively, shows that the PCR results in general correlate well with those 
obtained from the microarrays, thus confirming that the microarray assay results accurately 
represent the transcript levels expressed in the NK cells before and after vitamin D substitution. 
 


















Figure 9: Fold change values for the AIF1 and CLEC7A genes per microarray 
4.2 COMPARISON I: DEFICIENCY – SUBSTITUTION 
4.2.1 Overview of Differentially Expressed Genes 
The Kolmogorov-Smirnov test (Figure 10 and Figure 11) confirmed the Gaussian distribution 
of our data. Thus, usage of parametric tests like t-test and ANOVA were feasible. 
 
Figure 10. Normal Q-Q plot of average log2 signal before supplementation 
The distribution of our data before vitamin D supplementation approximates the expected Gaussian 













Figure 11. Normal Q-Q plot of average log2 signal after supplementation 
The distribution of our data after vitamin D supplementation approximates the expected Gaussian 
distribution (p < 0.001). 
A total of 505 transcripts are significantly differently expressed before and after vitamin D 
supplementation for a p-value of < 0.01 (Figure 12). Hierarchical clustering enables a quick 
overview of the large amounts of data generated by such analyses. Furthermore, transcripts 
in the scatter plot (Figure 13) do not appear to deviate from the midline, again indicating the 
small effect of the intervention. The heatmap (Figure 14) displays that vitamin D 
supplementation has only a small effect on the NK-cell transcriptome. 
Principal component Analysis (PCA) projects the summary of all transcripts as a vector for 
each individual into a 3D space. As can be seen, the samples do not seem to form clusters 
based on vitamin D levels. Thus, no clearly changed expression pattern can be observed that 
is clearly attributable to supplementation. There is, however, a clear spatial separation for sex 
(Figure 15). 
However, the PCA shows for all but one subject (sample 73) a substantial influence of the 
application (same volunteers prior to and post stimulation have the same color). It is clear that 
vitamin D supplementation has an effect on the individual subject, but intrasubject variability is 






Figure 12: Volcano plot of log2 p-values versus log2 fold change 
Each dot represents one single gene. Dots located on the left of the fold change value “1” represent 
upregulated genes, and those located on the right downregulated genes after supplementation of 
vitamin D3. The distance from the center of the graph (fold change value “1”) correlates with the 
magnitude of differential expression. In addition, the greater the distance from the x-axis, the lower is 
the p-value for statistical significance. Only transcripts with statistically significant differential expression 
(before multiple correction) for p < 0.01 are colored. Red signifies upregulated and blue downregulated 






Figure 13: Scatter plot 
The scatter plot demonstrates the distribution of the log2-transformed expression values between the 
two vitamin D states. The more a dot deviates from the imaginary diagonal upwards along the y axis, 
the more the gene was downregulated after substitution with vitamin D and vice versa. A perfect diagonal 
would indicate that the supplementation had no effect on the transcriptome. Statistically significantly 
differently expressed transcripts are shown as colored dots. Red signifies higher and blue lower 
expression after substitution of vitamin D3. Some deviation from the midline diagonal is noted in both 
directions which implies that vitamin D had a slight effect on the NK cell transcriptome both in terms of 
upregulating some genes and in downregulating others. More upregulated genes than downregulated 






Figure 14: Hierarchical clustering 
Hierarchical clustering based on the expression profile of transcripts that are up- or down-regulated 
based on p < 0.05 across the two different vitamin D levels. The color scale represents log2-transformed 
expression of the single gene samples. Brighter green represents lower expression and brighter red 








Figure 15: Principal component analysis – 1 
Red indicates samples before and blue after vitamin D supplementation. Cubes indicate males and 
spheres indicate females. The individual samples do not seem to form clusters based on vitamin D 
levels. Thus, no clearly changed expression pattern could be observed which clearly is attributable to 
supplementation. However, a clear spatial separation for sex is noted (males concentrate in the upper 
part of the diagram, females in the lower part). 
 
 
Figure 16: Principal component analysis – 2 
Different colors represent the individual subjects, spheres indicate vitamin D deficiency and cubes 
indicate samples after substitution. Individual samples are well separated in the 3D space, especially 
samples 71, 73, 74, 75 and 99 in the bottom of the diagram. This highlights that individual transcriptome 






4.2.2 Differentially Expressed Genes  
Of the total 505 transcripts differentially expressed after vitamin D application with p-values of 
< 0.01, only 256 have a well-established annotation to a specific coding or non-coding locus. 
No single gene remains significant after correction for multiple testing in the sex-independent 
analysis. This is a common problem of exome-wide analyses: the so-called “large P, small N” 
problem. It means that there are only a few data points “N” (samples, in our case 8 test 
subjects) but a large number of “P” (transcripts, in our case > 40.000) for each data point. 
Upregulated transcripts are listed in Table 17, whereas Table 18 shows downregulated 
transcripts. Table 19 displays genes related to the immune system or vitamin D signaling 
according to the GO Database. 
Table 17: Upregulated transcripts after supplementation of vitamin D3 scoring p < 0.01 
Gene Description Gene Description 
CDH19 
cadherin 19, type 2  
LINC01144 
long intergenic non-protein 
coding RNA 1144  
CELSR3-
AS1 
CELSR3 antisense RNA 1 
(head to head)  
LINC01456 
long intergenic non-protein 





sulfotransferase 15  
LINC01624 
long intergenic non-protein 





leucine rich repeat containing 
42  
CRELD2 
cysteine rich with EGF-like 
domains 2  
LRRC74A 
leucine rich repeat containing 
74A  
CRSP8P 
mediator complex subunit 
27 pseudogene  
MAP4K1 
mitogen-activated protein 
kinase kinase kinase kinase 1  
CTDNEP1 
CTD nuclear envelope 
phosphatase 1  
MED24 mediator complex subunit 24  
CUEDC2 CUE domain containing 2  MIR1244-1 microRNA 1244-1  
CYP21A1P 
cytochrome P450, family 
21, subfamily A, polypeptide 
1 pseudogene  
MIR548T microRNA 548t  
DDX39A 
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 39A  
MIR570 microRNA 570  
DENND6B 
DENN/MADD domain 
containing 6B  
MT1B metallothionein 1B  




DRD2 dopamine receptor D2  MYBL2 
v-myb avian myeloblastosis 
viral oncogene homolog-like 2  
EEF1A2 
eukaryotic translation 
elongation factor 1 alpha 2  
MYO7A myosin VIIA  
EIF5AL1 
eukaryotic translation 
initiation factor 5A-like 1  
NAV2-AS5 NAV2 antisense RNA 5  
ELFN1 
extracellular leucine-rich 
repeat and fibronectin type 
III domain containing 1  
NRG4 neuregulin 4  
EPB41L1 
erythrocyte membrane 
protein band 4.1-like 1  
OR52W1 
olfactory receptor, family 52, 
subfamily W, member 1  
EXOC6B 
exocyst complex 
component 6B  
P4HA2 
prolyl 4-hydroxylase, alpha 
polypeptide II  
F9 coagulation factor IX  PCBP4 poly(rC) binding protein 4  
FAM189B 
family with sequence 
similarity 189, member B  
PERP 
PERP, TP53 apoptosis 
effector  
FAM217A 
family with sequence 
similarity 217, member A  
PI4KA 
phosphatidylinositol 4-kinase, 
catalytic, alpha  
FAM219A 
family with sequence 
similarity 219, member A  
PI4KAP1 
phosphatidylinositol 4-kinase, 
catalytic, alpha pseudogene 1  
FAM25C 
family with sequence 
similarity 25, member C  
PKD2L1 
polycystic kidney disease 2-
like 1  
FAM53A 
family with sequence 
similarity 53, member A  
PLXDC1 plexin domain containing 1  
FBL fibrillarin  POLR2L 
polymerase (RNA) II (DNA 
directed) polypeptide L, 
7.6kDa  
FBLN7 fibulin 7  PPM1M 
protein phosphatase, 
Mg2+/Mn2+ dependent, 1M  
FBXL6 
F-box and leucine-rich 
repeat protein 6  
PPP1R15B 
protein phosphatase 1, 
regulatory subunit 15B  
FN1 fibronectin 1  PRAMEF2 PRAME family member 2  
GPR146 
G protein-coupled receptor 
146  
PRPF31 
pre-mRNA processing factor 
31  
HIST1H4F histone cluster 1, H4f  PRR23D2 
proline rich 23 domain 
containing 2  
HLA-C 
major histocompatibility 
complex, class I, C  
PRRT3 
proline-rich transmembrane 




HPSE2 heparanase 2 (inactive)  PTPRCAP 
protein tyrosine phosphatase, 





coding RNA  
PXMP2 
peroxisomal membrane 
protein 2  
IFITM5 
interferon induced 
transmembrane protein 5  
RARRES3 
retinoic acid receptor 
responder (tazarotene 
induced) 3  
IFNL3 interferon, lambda 3  RASA4B RAS p21 protein activator 4B  
IL17RE interleukin 17 receptor E  RASL10B 
RAS-like, family 10, member 
B  
IL2RB interleukin 2 receptor, beta  RETN resistin  
INO80E INO80 complex subunit E  RHBDF1 
rhomboid 5 homolog 1 
(Drosophila)  
ITGAM 
integrin, alpha M 
(complement component 3 
receptor 3 subunit)  
RNU5D-1 RNA, U5D small nuclear 1  
ITGAX integrin alpha X  RPH3AL 
rabphilin 3A-like (without C2 
domains)  
IVL involucrin  RPL21P28 
ribosomal protein L21 
pseudogene 28  
KDM8 
lysine (K)-specific 
demethylase 8  
RPL23AP87 
ribosomal protein L23a 
pseudogene 87  
KIF25 kinesin family member 25  RPS27 ribosomal protein S27  
KRT17 keratin 17, type I  SEC11A 
SEC11 homolog A, signal 
peptidase complex subunit  
KRTAP22-2 




endophilin B2  
KRTAP5-1 
keratin associated protein 
5-1  
SLPI 
secretory leukocyte peptidase 
inhibitor  
LIN7A 
lin-7 homolog A (C. 
elegans)  
SMARCB1 
SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily b, member 1  
LINC00619 
long intergenic non-protein 
coding RNA 619  
SNAR-I 
small ILF3/NF90-associated 
RNA I  
LINC00881 
long intergenic non-protein 
coding RNA 881  
SNORA35 
small nucleolar RNA, H/ACA 





long intergenic non-protein 
coding RNA 1144  
SNORD116-
14 
small nucleolar RNA, C/D box 
116-14  
LINC01456 
long intergenic non-protein 
coding RNA 1456  
SNORD20 
small nucleolar RNA, C/D box 
20  
LINC01624 
long intergenic non-protein 
coding RNA 1624  
SNORD32B 
small nucleolar RNA, C/D box 
32B  
LRRC42 
leucine rich repeat 
containing 42  
SOX13 SRY box 13  
LRRC74A 
leucine rich repeat 






kinase kinase kinase kinase 
1  
SPINK1 
serine peptidase inhibitor, 
Kazal type 1  
MED24 
mediator complex subunit 
24  
SSH3 
slingshot protein phosphatase 
3  
MIR1244-1 microRNA 1244-1  
STARD4-
AS1 
STARD4 antisense RNA 1  
MIR548T microRNA 548t  STARD9 
StAR-related lipid transfer 
domain containing 9  
MIR570 microRNA 570  TAAR3 
trace amine associated 
receptor 3 
(gene/pseudogene)  
MT1B metallothionein 1B  THOP1 thimet oligopeptidase 1  
MTRNR2L5 MT-RNR2-like 5  TOX2 
TOX high mobility group box 
family member 2  
MYBL2 
v-myb avian myeloblastosis 
viral oncogene homolog-like 
2  
TP53I13 
tumor protein p53 inducible 
protein 13  
MYO7A myosin VIIA  TRAV8-4 




transmembrane protein 5  
TRIM51HP 
tripartite motif-containing 
51H, pseudogene  
IFNL3 interferon, lambda 3  TTTY13 
testis-specific transcript, Y-
linked 13 (non-protein coding)  
IL17RE interleukin 17 receptor E  UCHL1 
ubiquitin C-terminal hydrolase 
L1  
IL2RB interleukin 2 receptor, beta  UPK3B uroplakin 3B  





integrin, alpha M 
(complement component 3 
receptor 3 subunit)  
USH2A 
Usher syndrome 2A 
(autosomal recessive, mild)  
ITGAX integrin alpha X  VAMP2 
vesicle associated membrane 
protein 2  
IVL involucrin  VIP vasoactive intestinal peptide  
KDM8 
lysine (K)-specific 
demethylase 8  
WBSCR16 
Williams-Beuren syndrome 
chromosome region 16  
KIF25 kinesin family member 25  YKT6 
YKT6 v-SNARE homolog (S. 
cerevisiae)  
KRT17 keratin 17, type I  ZNF324 zinc finger protein 324  
KRTAP22-2 
keratin associated protein 
22-2  
ZNF692 zinc finger protein 692  
KRTAP5-1 
keratin associated protein 
5-1  
ZNF728 zinc finger protein 728  
LIN7A 
lin-7 homolog A (C. 
elegans)  
ZNF733P 
zinc finger protein 733, 
pseudogene  
LINC00619 
long intergenic non-protein 
coding RNA 619  
ZNF788 
zinc finger family member 
788  
LINC00881 
long intergenic non-protein 
coding RNA 881  
  
Table 18: Downregulated transcripts after supplementation of vitamin D3 scoring p < 
0.01 
Gene Description Gene Description 
ADORA2B adenosine A2b receptor  LRRC1 
leucine rich repeat containing 
1  
AFF4 
AF4/FMR2 family, member 
4  
LRRFIP2 
leucine rich repeat (in FLII) 
interacting protein 2  
ANAPC4 
anaphase promoting 








phosphoprotein 32 family 
member B  




ANXA8L1 annexin A8-like 1  METTL14 methyltransferase like 14  
ASIP agouti signaling protein  MGC16025 uncharacterized LOC85009  
ATP11C ATPase, class VI, type 11C  MIEF1 
mitochondrial elongation 
factor 1  
BBS5 Bardet-Biedl syndrome 5  MIR1-1 microRNA 1-1  
BLOC1S6 
biogenesis of lysosomal 
organelles complex-1, 
subunit 6, pallidin  
MIR140 microRNA 140  
C15orf57 
chromosome 15 open 
reading frame 57  
MIR3175 microRNA 3175  
C16orf46 
chromosome 16 open 
reading frame 46  
MIR330 microRNA 330  
CAMTA1 
calmodulin binding 
transcription activator 1  
MIR4496 microRNA 4496  
CCDC81 
coiled-coil domain 
containing 81  
MIR933 microRNA 933  
CCR10 
chemokine (C-C motif) 
receptor 10  
NFATC4 
nuclear factor of activated T-
cells, cytoplasmic, 
calcineurin-dependent 4  
CCSAP 
centriole, cilia and spindle-
associated protein  
NKAIN2 
Na+/K+ transporting ATPase 
interacting 2  
CCT2 
chaperonin containing 
TCP1, subunit 2 (beta)  
OPCML 
opioid binding protein/cell 
adhesion molecule-like  
CDC14C cell division cycle 14C  OR6C70 
olfactory receptor, family 6, 
subfamily C, member 70  
CDH13 cadherin 13  PADI4 
peptidyl arginine deiminase, 
type IV  
CDKL5 
cyclin-dependent kinase-
like 5  
PGRMC2 
progesterone receptor 
membrane component 2  
CEP57L1 
centrosomal protein 57kDa-
like 1  
PKN2 protein kinase N2  
CHORDC1 
cysteine and histidine rich 
domain containing 1  
PLA2G4A 





containing linker protein 
family, member 4  
PLEKHH2 
pleckstrin homology domain 
containing, family H (with 





cms1 ribosomal small 
subunit homolog (yeast)  
PRKCH protein kinase C, eta  
CTRB1 chymotrypsinogen B1  PRR3 proline rich 3  
CYTIP 
cytohesin 1 interacting 
protein  
PSMC6 
proteasome 26S subunit, 
ATPase 6  
DEFB124 defensin, beta 124  PTGER4 
prostaglandin E receptor 4 
(subtype EP4)  
DENND5B-
AS1 
DENND5B antisense RNA 
1  
RAD51AP2 RAD51 associated protein 2  
DHX15 
DEAH (Asp-Glu-Ala-His) 
box helicase 15  
RBM44 RNA binding motif protein 44  
DICER1 
dicer 1, ribonuclease type 
III  
RGPD1 
RANBP2-like and GRIP 
domain containing 1  
DISP2 
dispatched homolog 2 
(Drosophila)  
RHOB 
ras homolog family member 
B  
DNAJA4 
DnaJ (Hsp40) homolog, 
subfamily A, member 4  
RIOK3 RIO kinase 3  
DOCK5 dedicator of cytokinesis 5  RPH3A rabphilin 3A  
DSCAM-IT1 DSCAM intronic transcript 1  RSPH10B 
radial spoke head 10 
homolog B (Chlamydomonas)  
EFCAB10 
EF-hand calcium binding 
domain 10  
SAYSD1 
SAYSVFN motif domain 






secretoglobin, family 2B, 
member 3, pseudogene  
EMC2 
ER membrane protein 
complex subunit 2  
SCUBE1 
signal peptide, CUB domain, 
EGF-like 1  
EXOG 
endo/exonuclease (5-3), 
endonuclease G-like  
SELK selenoprotein K  
FAM208B 
family with sequence 
similarity 208, member B  
SENP2 
SUMO1/sentrin/SMT3 
specific peptidase 2  
FBXW9 
F-box and WD repeat 
domain containing 9  
SENP5 
SUMO1/sentrin specific 
peptidase 5  
FEM1C 
fem-1 homolog c (C. 
elegans)  
SERBP1 
SERPINE1 mRNA binding 
protein 1  







FYVE, RhoGEF and PH 
domain containing 5 
pseudogene 1  
SMCHD1 
structural maintenance of 
chromosomes flexible hinge 
domain containing 1  
GABPB1-
AS1 
GABPB1 antisense RNA 1  SMNDC1 
survival motor neuron domain 
containing 1  
GACAT2 
gastric cancer associated 




small nucleolar RNA, C/D box 
114-3  
GCOM1 GRINL1A complex locus 1  SPINT1 
serine peptidase inhibitor, 
Kunitz type 1  
GPATCH2L 
G-patch domain containing 
2 like  




protein 1 light chain 3 beta 
pseudogene  
TAOK1 TAO kinase 1  
HACD1 
3-hydroxyacyl-CoA 
dehydratase 1  
TPI1P3 
triosephosphate isomerase 1 
pseudogene 3  
HOXD12 homeobox D12  TRBV5-4 






Ts translation elongation 




subunit 1  
TTC39B 
tetratricopeptide repeat 
domain 39B  
IP6K2 
inositol hexakisphosphate 
kinase 2  
UGT2B17 
UDP glucuronosyltransferase 
2 family, polypeptide B17  
IPO11 importin 11  UPRT 
uracil 
phosphoribosyltransferase 
(FUR1) homolog (S. 
cerevisiae)  
KCNE1 
potassium channel, voltage 
gated subfamily E 
regulatory beta subunit 1  
VWC2L-IT1 VWC2L intronic transcript 1  
KIF15 kinesin family member 15  ZEB2 
zinc finger E-box binding 
homeobox 2  
KIF1B kinesin family member 1B  ZNF709 zinc finger protein 709  
KRTAP4-2 
keratin associated protein 
4-2  












TRAV8-4 T cell receptor alpha variable 8-4  -1.54 0.00761 
MAP4K1 
mitogen-activated protein kinase kinase 
kinase kinase 1  
-1.34 0.00388 
IFNL3 interferon, lambda 3  -1.30 0.00671 
IL17RE interleukin 17 receptor E  -1.24 0.00443 
POLR2L 
polymerase (RNA) II (DNA directed) 
polypeptide L, 7.6kDa  
-1.23 0.00904 
VIP vasoactive intestinal peptide  -1.22 0.00146 
C1orf147 chromosome 1 open reading frame 147  -1.21 0.00525 
IFITM5 interferon induced transmembrane protein 5  -1.19 0.00350 
SLPI secretory leukocyte peptidase inhibitor  -1.19 0.00999 
DRD2 dopamine receptor D2  -1.18 0.00661 
ITGAM 
integrin, alpha M (complement component 3 
receptor 3 subunit)  
-1.16 0.00232 
IL2RB interleukin 2 receptor, beta  -1.13 0.00802 
VAMP2 vesicle associated membrane protein 2  -1.10 0.00815 
MED24 mediator complex subunit 24  -1.09 0.00743 
NRG4 neuregulin 4  -1.09 0.00871 
HLA-C major histocompatibility complex, class I, C  -1.08 0.00426 
CCR10 chemokine (C-C motif) receptor 10  1.12 0.00455 
PSMC6 proteasome 26S subunit, ATPase 6  1.13 0.00591 
PTGER4 prostaglandin E receptor 4 (subtype EP4)  1.16 0.00388 
SRPK1 SRSF protein kinase 1  1.18 0.00589 
NFATC4 
nuclear factor of activated T-cells, 






biogenesis of lysosomal organelles 
complex-1, subunit 6, pallidin  
1.22 0.00058 
DEFB124 defensin, beta 124  1.23 0.00058 
TRBV5-4 T cell receptor beta variable 5-4  1.30 0.00337 
PADI4 peptidyl arginine deiminase, type IV  1.41 0.00820 
PLA2G4A 






Selection of genes associated with the immune system or vitamin D signaling according to the GO 
Database with a significance level of p < 0.01. A negative fold change means increased expression, and 




First, we could show that known vitamin D-dependent genes were differentially expressed for 
an uncorrected p value < 0.01. MED24, being upregulated, encodes one of the components of 
the so-called mediator complex, which is a transcriptional coactivator complex required for 
gene expression. The mediator complex is directly involved in VDR mediated gene expression 
[108]. Another gene associated with vitamin D, the PLA2GA4 gene, is downregulated after 
supplementation. This encodes the phospholipase A2, group IVA (cytosolic, calcium-
dependent) protein PLA2GA4, which belongs to a group of 4A phospholipases, whose 
expression is influenced by 1,25-(OH)2D3 in mast cells [141]. 
Second, the expression of genes with established roles in NK-cell regulation, which are 
affected from vitamin D supplementation. For instance, dopamin receptors have shown to 
modulate NK-cell cytotoxicity. Agonists of the dopamine receptor D2 (DRD2) particularly have 
been shown to suppress NK cells through the D3R/D4R-cAMP-PKA-CREB signaling pathway 
[167]. The DRD2 gene is upregulated in our study.  
In contrast, the BLOC1S6 gene is downregulated. Its product, BLOC16S (biogenesis of 
lysosomal organelles complex-1, subunit 6, pallidin) is a component of the BLOC-1 complex 
which is necessary for lysosome function in NK cells. Mutations of the BLOC1S6 gene lead to 
development of the Hermansky-Pudlak syndrome, which is characterized from abnormal 
function of lysosomes and lysosome-related organelles and consequently NK-cell dysfunction 
[11]. 
Studies have demonstrated that prostaglandin E2 receptor 4 (EP4), which is encoded by the 
PTGER4 gene, suppresses NK-cell function [56]. It is therefore consistent with our findings 
that it is downregulated following vitamin D substitution. The ITGAM gene is upregulated 
following vitamin D substitution. It encodes Integrin α-M (CD11b), which is involved in several 
immune reaction processes such as phagocytosis, chemotaxis, cell-mediated cytotoxicity and 
cellular activation and is expressed in macrophages, monocytes, granulocytes and NK cells 
[132]. Finally, higher HLA-C (human leukocyte antigen) expression on NK cells has been 
clearly associated with decreased degranulation and in turn lower cytolytic activity. In contrast 
to what would be expected, NK cells in our study express higher HLA-C levels after vitamin D 
supplementation [86].  
Furthermore, the influence of vitamin D serum levels can also be shown for some genes 
involved in cytokine regulation. NFATC4 is downregulated after vitamin D supplementation. Its 
gene product, the nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 
protein, is a transcription modulator in lymphatic cells. Its overexpression suppresses Il-2 
production in T cells and its downregulation is crucial for adequate cytokine-producing activity 
of T cells [68]. NFAT knockdown in mice leads to enhanced NK cell activity after exposure to 




Lambda interferons (IFN-λ) belong to the type III interferon family and are a component of the 
innate immune defense to viruses, bacteria, and fungi. They have been shown to influence 
NK-cell responses to viral infection [22]. This mechanism is mediated through monocyte 
activation and production of IL-12 p40, which in turn leads to increased IFN-γ secretion from 
NK cells [75].The IFNL3 gene, responsible for IFN-λ3 (also called IL-28B), was upregulated 
after supplementation with 1,25-(OH)2D3. 
Another cytokine axis involving IL-17, for which enhancement of NK-cell function has been 
postulated, is influenced by vitamin D treatment. IL17RE is upregulated in our experiment. It 
encodes the interleukin 17 receptor E, which is expressed on mRNA-level intracellularly but 
not on the surface [3]. 
More importantly, the beta subunit of the interleukin receptor 2 (IL2RB gene) was upregulated 
in this study. IL-2 signaling through the IL-2 receptor is crucial for NK-cell function, as described 
in 2.1.1 (page 2). The specific role of IL-2 in NK-cell-mediated ADCC is elicited in 2.1.5 (page 
8). Affinity of IL-2 to its receptor depends on the receptors chain composition. Low-affinity 
binding is associated with the alpha chain, intermediate-affinity binding with the beta chain, 
and high-affinity binding with a complex of the alpha and beta subunits. A gamma chain which 
associates with the beta chain has also been described [152].  
Signal cascades also seem to be influenced by vitamin D substitution. After receptor activation 
of the NK cell, intracellular activation signals are mediated through the phosphorylation of the 
mitogen activated protein kinase (MAPK) pathway[57]. The MAPK family includes three kinase 
families, the extracellular signal-regulated kinases (ERK), the p38 kinases and the c-Jun N-
terminal kinases (JNK) [127]. In our experiment, the gene MAP4K1 is upregulated. This gene 
encodes the mitogen-activated protein kinase kinase kinase kinase 1, which is involved in the 
JNK pathway. While adequate NK-cell cytotoxicity requires all three kinase families, NK-cell-
mediated ADCC specifically has been shown to be dependent of the p38 and ERK families 
[146]. Upstream activation of the MAPK signaling pathway depends partly on receptor kinases 
expressed on the cell surface. One of these is the ErbB4/Her4 receptor, which requires specific 
binding with the neuregulin 4 transmembrane protein for its activation [52]. NGR4, the gene 
coding neuregulin 4, is found to be downregulated in our experiment. 
Moreover, vitamin D supplementation affects genes which are generally involved in the 
immune response. The expression of two variable chains of the T-cell receptor: the alpha 
variable 8-4 (TRAV8-4) and the beta variable 5-4 (TRBV5-4) was found to be vitamin D 
dependent. TRAV8-4 was upregulated, on the other hand TRBV5-4 showed reduced 
expression in higher vitamin D serums levels. In NKT cells, which also express a T-cell receptor 
(see page 3, 2.1.1.3), the alpha chain has been shown to express an invariant rearrangement 




exists, which show alpha chain diversity including Vα3-Jα9 or Vα8. However, various 
experimental difficulties have so far prevented a more detailed characterization in humans [49]. 
More diversity has been demonstrated for the beta chain of the receptor, with five proven V 
beta gene families: V beta 2, 7, 8, 11, and 13 [119],[49].  
DNA-directed RNA polymerases I, II, and III subunit RPABC5, encoded by the POLR2 gene, 
is involved in the recognition process of foreign RNA in the innate immune system [15]. It is 
upregulated in our experiment. 
The vasoactive intestinal peptide (VIP gene), upregulated in our study, is a neuropeptide which 
is excreted in lymphatic as well as neural cells and has been shown to possess potent anti-
inflammatory function by regulating the production of both anti- and pro-inflammatory 
mediators [40]. 
The gene product of the IFITM5 gene, Interferon induced transmembrane protein 5, has been 
linked to viral response [87]. It is upregulated in the vitamin D supplemented state. Other 
transcripts like C1orf147 (chromosome 1 open reading frame 147), which is upregulated too, 
has only been linked vaguely in expression studies with the immune system. The same applies 
for the PSMC6 gene encoding the enzyme 26S proteasome AAA-ATPase subunit Rpt4, and 
the SRPK1 gene encoding SRSF protein kinase 1, both downregulated in our experiment 
[9,27].  
Lastly, some of the differentially expressed genes have no known roles in NK cells. The 
secretory leukocyte peptidase inhibitor, derived from the SLPI gene, is an enzyme that has 
antimicrobial properties in addition to its function as a protease inhibitor. It is upregulated after 
supplementation with vitamin D. However, its function in NK cells is not known [43]. The same 
holds true for VAMP2, coding the Vesicle-associated membrane protein 2, which h has been 
shown to play a role in the fusion of membrane-enveloped vesicles and is also upregulated. 
The CCR10 gene product, named C-C chemokine receptor type 10, which was 
downregulated, has also no function in NK cells [32],[80]. Another downregulated gene with 
no specific role on NK cells is PADI4 [169]. It encodes the peptidyl arginine deiminase – type 
IV, which is involved in post-translational modification. Defensins are antimicrobial peptides 
expressed mainly by epithelial cells and neutrophils. The DEFB124 gene encoding defensin 
beta 124, is downregulated in our study. Although NK cells have been shown to produce alpha 





4.3 COMPARISONS BASED ON VITAMIN D STATUS UND SEX 
As discussed above, using the TAC Software, we performed two-way ANOVA to compare the 
following four groups, as explained in 3.4.2, page 35: 1) deficient females, 2) deficient males, 
3) supplemented females, and 4) supplemented males. The following criteria were used when 
testing for statistical significance: a p-value in the ANOVA test of < 0.01 and a decrease or 
increase in gene expression after vitamin D supplementation by a factor 1.5. Correction for 
multiple testing was performed with the false discovery rate (FDR) method for a q value < 0.05. 
A summary of comparisons II-IV is provided in Figure 17. 
 
Figure 17: Summarized ANOVA results for comparisons II-VI 
The diagram shows the number of genes statistically significant affected by vitamin D, which were either 
up-regulated (red) or down-regulated (green). Shown are the different comparisons that have been 
made (from top to bottom): Comparison II, III, IV, V, and IV 
4.3.1 Comparison II: Male – Female 
After correction for multiple testing, 38 transcripts showed a significantly altered expression 






















channel, subfamily C, 
member 3 
chr4 3.31 2.35 1.94 0.0044 
DDX43 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
43 
chr6 2.78 4.6 -3.53 0.0162 
ZFX 
zinc finger protein, X-
linked 
chrX 6.07 5.36 1.63 0.0399 
XIST 
X inactive specific 
transcript (non-protein 
coding) 
chrX 10.9 2.42 357.08 7.21E-12 
TSIX 
TSIX transcript, XIST 
antisense RNA 
chrX 5.72 3.26 5.52 9.76E-08 
JPX 
JPX transcript, XIST 
activator (non-protein 
coding) 
chrX 7.99 7.34 1.57 0.0014 
EIF1AX 
eukaryotic translation 
initiation factor 1A, X-
linked 
chrX 8.29 7.64 1.57 0.0129 
CA5B 
carbonic anhydrase VB, 
mitochondrial 
chrX 6.79 5.78 2.01 0.0292 
ZFY 
zinc finger protein, Y-
linked 
chrY 2.42 5.37 -7.75 5.86E-06 
USP9Y 
ubiquitin specific 
peptidase 9, Y-linked 








chrY 2.33 7.23 -29.9 1.36E-09 
TTTY15 
testis-specific transcript, 
Y-linked 15 (non-protein 
coding) 
chrY 2.54 8.28 -53.34 1.67E-10 
TTTY14 
testis-specific transcript, 
Y-linked 14 (non-protein 
coding) 
chrY 3.36 5.17 -3.53 1.15E-05 
TTTY14 
testis-specific transcript, 
Y-linked 14 (non-protein 
coding) 
chrY 1.76 2.89 -2.18 0.0005 
TTTY10 
testis-specific transcript, 
Y-linked 10 (non-protein 
coding) 





thymosin beta 4, Y-
linked 
chrY 2.77 4.49 -3.3 7.60E-05 
RPS4Y1 
ribosomal protein S4, 
Y-linked 1 
chrY 2.64 4.93 -4.89 0.0032 
PRKY 
protein kinase, Y-linked, 
pseudogene 
chrY 3.68 8.59 -29.99 1.79E-08 
LINC00278 
long intergenic non-
protein coding RNA 278 




chrY 2.54 7.76 -37.32 2.47E-09 
EIF1AY 
eukaryotic translation 
initiation factor 1A, Y-
linked 
chrY 2.52 6.02 -11.3 0.0004 
DDX3Y 
DEAD (Asp-Glu-Ala-
Asp) box helicase 3, Y-
linked 
chrY 2.11 8.22 -68.77 2.57E-10 




chrY 2.51 6.63 -17.43 8.14E-06 
ANOS2P anosmin 2, pseudogene chrY 1.66 3.76 -4.31 0.0001 
Differentially expressed genes between males and females (comparison II, p < 0.05) are listed here. A 
negative fold change signifies higher expression in the male and a positive fold change higher 
expression in the female. Genes not located on sex chromosomes are marked in bold. 
Unsurprisingly, genes on the Y chromosome were overexpressed in males, whereas genes on 
the X chromosome were overexpressed in females. Interestingly, DDX43 and TRPC3, 
although not located on either sex chromosome, are also found to be sex dependent. The 
DEAD-box protein DDX43, also called HAGE, is an RNA/DNA helicase that is required for the 
complete unwinding of the nucleic acid. The DDX43 gene is located on chromosome 6 in 
humans and significant more copies of this gene can be found in males [142]. TRPC3 is a 
gene located on chromosome 4 and encodes the calcium cation channel TRPC3 (transient 
receptor potential cation channel, subfamily C, member 3). This cation channel has been linked 
to lymphocyte and NK-cell response to haptens [50]. The TRPC3 gene was more strongly 
expressed in women.  
4.3.2 Comparison III: Differentially Expressed Genes – Female Subjects 
The following criteria for statistical significance were used in the gender specific analysis: p < 
0.01 and increase/decrease of fold change by a factor of 1.5. After correction for multiple 




presented in Table 21. Genes involved in the immune response, vitamin D response, or NK 
cell physiology are shown in bold. 
Table 21: Comparison III – Differentially expressed genes in females 
Gene Symbol Description 
Fold 
Change 
TRIM51 tripartite motif-containing 51 -2.44 
MIR3180-5; 
MIR3180-4 
microRNA 3180-5; microRNA 3180-4 -2.06 
ZNF733P zinc finger protein 733, pseudogene -1.93 
TRBV7-6 T cell receptor beta variable 7-6 -1.93 
WLS wntless Wnt ligand secretion mediator -1.88 
KRTAP5-11 keratin associated protein 5-11 -1.87 
SAMD5 sterile alpha motif domain containing 5 -1.77 
MIR4330 microRNA 4330 -1.68 
NBPF13P neuroblastoma breakpoint family, member 13, pseudogene -1.66 
RGS8 regulator of G-protein signaling 8 -1.63 
SYDE2 synapse defective 1, Rho GTPase, homolog 2 (C. elegans) -1.61 
IGKV5-2 immunoglobulin kappa variable 5-2 -1.6 
SNORD116-20; 
SNORD116@ 
small nucleolar RNA, C/D box 116-20; small nucleolar RNA, C/D 
box 116 cluster 
-1.59 
MIR187 microRNA 187 -1.57 
ZNF649-AS1 ZNF649 antisense RNA 1 -1.56 
OR5D14 olfactory receptor, family 5, subfamily D, member 14 -1.53 
HULC hepatocellular carcinoma up-regulated long non-coding RNA -1.52 
PART1 prostate androgen-regulated transcript 1 (non-protein coding) -1.51 
NPS neuropeptide S -1.5 
PTPRO protein tyrosine phosphatase, receptor type, O 1.51 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 1.56 
LINC00853 long intergenic non-protein coding RNA 853 1.56 
L1TD1 LINE-1 type transposase domain containing 1 1.57 
KCNE1 
potassium channel, voltage gated subfamily E regulatory beta 
subunit 1 
1.58 
CEP295NL CEP295 N-terminal like 1.6 
ARHGAP5 Rho GTPase activating protein 5 1.6 
CNP 2,3-cyclic nucleotide 3 phosphodiesterase 1.62 
SLC31A2 solute carrier family 31 (copper transporter), member 2 1.63 




KDM1B lysine (K)-specific demethylase 1B 1.64 
USP12-AS2 USP12 antisense RNA 2 (head to head) 1.67 
GCA grancalcin, EF-hand calcium binding protein 1.69 
MIR370 microRNA 370 1.7 
DUSP3 dual specificity phosphatase 3 1.7 
WFDC10B WAP four-disulfide core domain 10B 1.72 
SLC24A4 




solute carrier family 37 (glucose-6-phosphate transporter), member 
2 
1.77 
CD99P1 CD99 molecule pseudogene 1 1.79 
FGD6 FYVE, RhoGEF and PH domain containing 6 1.82 
RPL23AP7 ribosomal protein L23a pseudogene 7 1.83 
TLR5 toll-like receptor 5 1.89 
CPM carboxypeptidase M 1.89 
MIR4309 microRNA 4309 1.91 
C9orf72 chromosome 9 open reading frame 72 1.93 
MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 1.97 
FZD1 frizzled class receptor 1 2.09 
SMPDL3A sphingomyelin phosphodiesterase, acid-like 3A 2.27 
IGSF6 immunoglobulin superfamily, member 6 2.41 
CFP complement factor properdin 2.68 
PAPSS2 3-phosphoadenosine 5-phosphosulfate synthase 2 2.89 
GAPT GRB2-binding adaptor protein, transmembrane 3.24 
MNDA myeloid cell nuclear differentiation antigen 3.74 
TLR8 toll-like receptor 8 3.77 
RNU6-53P RNA, U6 small nuclear 53, pseudogene 4.24 
Genes which were significantly differentially expressed (p < 0.01) and an increase/decrease of fold 
change at least by a factor of 1.5 are shown. A negative fold change signifies higher expression and, 
conversely, a positive fold change indicates a corresponding reduction in expression after vitamin D 
supplementation. Genes involved in the immune response, vitamin D response, or NK cell physiology 
are marked bold. 
The role of T cell receptor chains in NKT cells are discussed in detail in 4.2.2, page 47. In 
females, TRBV7-6 gene, encoding the beta T cell receptor beta variable chain 7-6, a 




Although immunoglobulins do not play a direct role in NK cells, antibody coating is crucial for 
ADCC. The upregulation of the IGKV5-2 (immunoglobulin kappa variable 5-2) gene in women 
must be seen in this context [155]. 
The P21 (Cdc42/Rac)-activated kinase 1 (encoded by the PAK1 gene) is involved in ERK 
signaling [64], whose importance in NK cell cytotoxicity in the MAPK-pathway is discussed in 
4.2.2 (page 47). In females, a lower expression is seen after 1,25(OH)2D3 supplementation.  
The Dual specificity protein phosphatase 3, encoded by the DUSP3 gene, and further 
members of the DUSP-subfamily negatively regulate members of the MAP kinase superfamily 
[78] (see also chapter 4.2.2, page 47). Due to its decreased expression under vitamin D, the 
negative regulatory effect of DUSP3 on the MAP kinase pathway is in turn reduced, i.e. it leads 
to increased NK-cell activity. This is consistent with the results of our study on the influence of 
vitamin D on NK-cell-mediated ADCC. 
The role of TLR in NK cells is described in chapter 2.1.4. (page 7). In females, the surface 
receptor TLR5 and the endosome receptor TLR8 are downregulated after supplementation of 
vitamin D. 
Receptors of the Frizzled family (Fzd) are expressed on NKT cells (at least FZD1 and FZD9) 
and represent the membrane bound receptors of Wnt-signaling, which modulates IL-4 and 
IFN-γ production. IFN-γ excretion is halted and later sustained in a time- and b-catenin 
dependent matter [72]. The FZD1 gene is downregulated in females. On the contrary, another 
gene product involved in the Wnt pathway is upregulated, the wntless Wnt ligand secretion 
mediator (encoded by the WLS gene). This protein is necessary for the secretion of Wnt 
proteins and their binding to FZD receptors [28,61,161].  
Complement factor properdin, encoded by the CPF gene, is the only known positive regulator 
of the alternative complement pathway. Its role in NK cells is the binding to NKp46 and has 
been shown to be crucial to defense against Neisseria meningitidis infection [159]. It is 
downregulated in females in our experiment. 
Lastly, the GAPT gene, encoding the GRB2-binding adaptor transmembrane protein, shown 
reduced expression after vitamin d supplementation. It has been linked to B cell proliferation 
and while it is expressed in NK cells, but its exact role is yet to be established [91]. 
4.3.3 Comparison IV: Differentially Expressed Genes – Male Subjects 
With p < 0.01 and an increase/decrease of fold change by a factor of 1.5, a total of 28 
transcripts with a well-established annotation were identified in male subjects after vitamin D 
supplementation. As in the previous analysis for the female subjects, after correction for 
multiple testing, no transcripts remain significant. In order to be able to formulate a hypothesis 










EIF5AL1 eukaryotic translation initiation factor 5A-like 1 -2.28 
MIR548T microRNA 548t -2.27 
MIR4476 microRNA 4476 -2.17 
GGT1; 
SNRPD3 
gamma-glutamyltransferase 1; small nuclear ribonucleoprotein D3 
polypeptide 
-2.16 
ARHGAP39 Rho GTPase activating protein 39 -1.82 
FGF12-AS3 FGF12 antisense RNA 3 -1.81 
TTTY14 testis-specific transcript, Y-linked 14 (non-protein coding) -1.71 
MIR4279 microRNA 4279 -1.68 
C9orf139 chromosome 9 open reading frame 139 -1.68 
SLC52A1 solute carrier family 52 (riboflavin transporter), member 1 -1.64 
SERPINA12 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 12 
-1.64 
TUBA3D tubulin, alpha 3d -1.62 
MIR125A microRNA 125a -1.61 
SEMA6A 
sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6A 
-1.59 
LRRC3 leucine rich repeat containing 3 -1.59 
EFCAB12 EF-hand calcium binding domain 12 -1.59 
SNRPN small nuclear ribonucleoprotein polypeptide N -1.55 
IFNL3 interferon, lambda 3 -1.54 
BIRC7 baculoviral IAP repeat containing 7 -1.52 
PLA2G4E-
AS1 
PLA2G4E antisense RNA 1 -1.51 
USP51 ubiquitin specific peptidase 51 1.51 
C5orf60 chromosome 5 open reading frame 60 1.54 
ASAP1-IT2 ASAP1 intronic transcript 2 1.64 
TPRX1 tetra-peptide repeat homeobox 1 1.66 
MGAM2 maltase-glucoamylase 2 (putative) 1.83 
ZSCAN5CP zinc finger and SCAN domain containing 5C, pseudogene 1.9 
MIR1827 microRNA 1827 1.92 
IFNG interferon, gamma 2.12 
Genes which were significantly differentially expressed (p < 0.01) and an increase/decrease of fold 
change at least by a factor of 1.5 are shown. A negative fold change signifies higher expression and, 
conversely, a positive fold change indicates a corresponding reduction in expression after vitamin D 
supplementation. Genes involved in the immune response, vitamin D response, or NK cell physiology 




In males, the INFL3 gene is shown to be upregulated after vitamin D supplementation. The 
role of its gene product was discussed in detail in chapter 4.2.2 on page 47.  
Most interestingly, the IFNG gene, which encodes IFN-γ, is downregulated in men after 
substitution with vitamin D. IFN-γ plays an important role in viral clearance and viral infection 
control. It induces maturation and activation of DCs and macrophages and promotes T cell 
response. Specifically, it inhibits differentiation into IL-4- and Il-17-producing CD4+ T cells (Th2 
and Th17) and induces differentiation into pro-inflammatory Th1 cells [112]. In target cells, IFN-
γ induces upregulation of intercellular adhesion molecule 1 (ICAM-1) which promotes NK-
target cell conjugation [154]. On the other hand, it can upregulate MHC-class I molecules, 
which, when expressed on cells targeted by NK cells, for instance tumors, function as an 
inhibitory KIR-ligand for NK-cell activation. Although IFN-γ plays a clear role in antiviral 
defense, it is due to this NK-cell inhibitory effect that its anti-tumor effects are less 
straightforward. In fact, in the presence of IFN-γ, NK cell-mediated tumor lysis may even be 
reduced. This is not only attributed to the afore mentioned overexpression of MHC-class I 
molecules on target cells, but also of other inhibitory ligand/receptor interactions like PD-L1, 
HLA-DR, CD95/FasR, and CD270/HVEM [6]. 
4.3.4 Comparison V: Female vs. Male in the Vitamin D Deficient State 
Finally, males and females were compared in the vitamin D deficient state and after vitamin D 
supplementation. The Venn diagram below (Figure 18) provides an overview of the 
differentially expressed transcripts in the two groups and highlights those with unique 






Figure 18: Venn diagram of comparisons II, V and VI 
The Venn diagram shows the number of differentially expressed genes between males and females, in 
the vitamin D deficient state (orange) and after substitution (blue). The purple area represents the genes, 
which are expressed differently between females and males but are independent of vitamin D status. 
26 transcripts were differentially expressed after correction for multiple testing between male- 
and female-derived NK cells in the deficient state (orange area in Figure 18). Coincidentally, 
after supplementation with vitamin D, the same number of transcripts was statistically 
significantly differentially expressed after adjustment for multiple testing between males and 
females (n = 26, blue area in Figure 18), but of those, only 24 were the same as in the deficient 
state (purple area in Figure 18) and two additional transcripts appeared. So, in total, 28 
transcripts with sex- and vitamin D-dependent expression were identified. Of those, 24 (85.7%) 
are independent of vitamin D status. Two transcripts were shown to be sex-specifically 
differentially expressed only in the vitamin D deficient state and two different transcripts could 
be identified after vitamin D substitution.  
Table 23 features the 18/26 genes (orange area in Figure 18) with known annotations which 
are differentially expressed by female and male NK cells in the deficient state. For one of the 
genes, RPS4Y1, overexpression in males compared to the female was higher in the vitamin D 
deficient state than after substitution. It is one of the two genes which encode the ribosomal 
protein S4. This is the only ribosomal protein known to be encoded by more than one g ene, 
specifically ribosomal protein S4, Y-linked gene (RPS4Y1) and ribosomal protein S4, X-linked 
(RPS4X) [172]. A recent study has also demonstrated that expression of the Y-linked gene is 
vitamin D dependent, but in this study it was upregulated after supplementation [128]. The 




Table 23: Comparison V – Differentially expressed genes – Female vs. male in the 









X inactive specific transcript (non-
protein coding) 
X 350.73 4.60E-10 
TSIX 
TSIX transcript, XIST antisense 
RNA 
X 6.11 4.35E-06 
ZFY zinc finger protein, Y-linked Y -6.57 0.0005 
USP9Y 
ubiquitin specific peptidase 9, Y-
linked 
Y -44.55 2.88E-08 
TXLNGY 
taxilin gamma pseudogene, Y-
linked 
Y -36.73 3.07E-08 
TXLNGY 
taxilin gamma pseudogene, Y-
linked 
Y -32.29 7.46E-08 
TTTY15 
testis-specific transcript, Y-linked 
15 (non-protein coding) 
Y -58.68 7.90E-09 
TTTY14 
testis-specific transcript, Y-linked 
14 (non-protein coding) 
Y -3.79 0.0002 
TMSB4Y thymosin beta 4, Y-linked Y -4.66 0.0005 
PRKY 
protein kinase, Y-linked, 
pseudogene 
Y -31.87 9.36E-07 
LINC00278 
long intergenic non-protein coding 
RNA 278 
Y -12.66 2.41E-05 
KDM5D lysine (K)-specific demethylase 5D Y -39.08 1.33E-07 
EIF1AY 
eukaryotic translation initiation 
factor 1A, Y-linked 
Y -12.03 0.0056 
DDX3Y 
DEAD (Asp-Glu-Ala-Asp) box 
helicase 3, Y-linked 
Y -70.44 1.59E-08 
CD24 CD24 molecule Y -6.32 0.0186 
BCORP1 BCL6 corepressor pseudogene 1 Y -16.46 0.0005 
ANOS2P anosmin 2, pseudogene Y -4.34 0.0069 
RPS4Y1 ribosomal protein S4, Y-linked 1 Y -5.29 0.0288 
Differentially expressed genes between females and males in the vitamin D deficient state (comparison 
V, p < 0.05) are presented here. A negative fold change signifies higher expression in the male and a 
positive fold change higher expression in the female. Genes with no differential expression after 




4.3.5 Comparison IV: Female vs. Male after Vitamin D Supplementation 
19/26 genes with established annotations (blue area in Figure 18) which show differential 
expression after correction for multiple testing between the two sexes after supplementation 
are listed in Table 24. The differential expression of two of those genes is not only sex- but 
also vitamin D-dependent. 
First, vitamin D substitution leads to increased expression of the JPX gene in females. Its gene 
product is a long noncoding RNA (lncRNA). It is located in the X-inactivation center and is 
involved in X chromosome inactivation in female mammals [144]. It is physiologically higher 
expressed in the female; however, restoration of vitamin D serum levels widens the RNA 
expression gap between the sexes.   
After vitamin D substitution a second probe for TTTY14 (Testis-Specific Transcript, Y-Linked 
14) was overexpressed in males. TTTY14 is another lncRNA class gene which is yet be studied 
in detail. Its expression in tissues outside testis is unclear. Furthermore, no known associations 
with vitamin D or the immune system exist [38]. 
Table 24: Comparison VI – Differentially expressed genes – Female vs. male after  









X inactive specific transcript (non-protein 
coding) 
X 374.13 4.47E-10 
TSIX TSIX transcript, XIST antisense RNA X 5.11 7.09E-06 
JPX 
JPX transcript, XIST activator (non-
protein coding) 
X 1.81 0.0059 
ZFY zinc finger protein, Y-linked Y -7.93 0.0001 
USP9Y ubiquitin specific peptidase 9, Y-linked Y -61.73 1.32E-08 
TXLNGY taxilin gamma pseudogene, Y-linked Y -30.67 4.46E-08 
TXLNGY taxilin gamma pseudogene, Y-linked Y -28.99 9.13E-08 
TTTY15 
testis-specific transcript, Y-linked 15 
(non-protein coding) 
Y -48.4 1.32E-08 
TTTY14 
testis-specific transcript, Y-linked 14 
(non-protein coding) 
Y -3.06 0.0015 
TTTY14 
testis-specific transcript, Y-linked 14 
(non-protein coding) 
Y -2.82 0.0009 
TMSB4Y thymosin beta 4, Y-linked Y -2.91 0.0287 





long intergenic non-protein coding RNA 
278 
Y -9.76 6.45E-05 
KDM5D lysine (K)-specific demethylase 5D Y -34.26 1.50E-07 
EIF1AY 
eukaryotic translation initiation factor 1A, 
Y-linked 
Y -8.96 0.0419 
DDX3Y 
DEAD (Asp-Glu-Ala-Asp) box helicase 
3, Y-linked 
Y -66.09 1.32E-08 
CD24 CD24 molecule Y -6.32 0.0128 
BCORP1 BCL6 corepressor pseudogene 1 Y -18 0.0003 
ANOS2P anosmin 2, pseudogene Y -4.39 0.0028 
 
Differentially expressed genes between females and males after vitamin D supplementation 
(comparison VI, p < 0.05) are presented here. A negative fold change signifies higher expression in the 
male and a positive fold change higher expression in the female. Genes with no differential expression 
in the vitamin D deficient state are marked in bold. 
 
4.4  PATHWAY ANALYSIS 
Pathway analysis was performed as described in 3.4.4, page 37. As mentioned afore, the first 
step in GSEA is to generate a ranked gene list. The top 50 upregulated and top 50 
downregulated transcripts on the list according to the metric used (Signal-to-Noise) are 
presented in Figure 19. Based on this ranked gene list, a number of selected, predefined gene 







































Figure 19: Heat map of the 50 most significant transcripts for each phenotype as per GSEA ranked list 
The heatmap demonstrates the correlation between the ranked genes and the phenotypes (columns on the left: 
deficiency, columns on the right: substitution). The expression values are represented in a color scale, where 
the range of colors (red, pink, light blue, dark blue) shows the range of expression values (high, moderate, low, 
lowest). The metric used was the default Signal2Noise metric. Only the top 50 downregulated and top 50 




4.4.1 NK-Cell Cytotoxicity Pathway 
The “NK-cell cytotoxicity pathway” was found to be significantly (p = 0.016) upregulated after 
vitamin D substitution (Table 25, Figure 20) within the prespecified gene subgroup. The genes, 
which shaped the enrichment score in the pathway, are listed in Table 26.  
Table 25: NK cell cytotoxicity pathway – Metrics 
Name ES NES p-value 
FDR 
q-value 
KEGG NATURAL KILLER CELL MEDIATED 
CYTOTOXICITY 
0.56 1.41 0.016 0.016 
The definition and calculation method of the enrichment score is described in in 3.4.4, page 37. The ES 
is normalized to adjust for variation on predefined gene set size. The FDR value is equal to the p-value 
in this case as no other gene set was included in this analysis. Abbreviations: ES: Enrichment Score, 
NES: Normalized Enrichment Score, FDR: false discovery rate, KEGG: Kyoto Encyclopedia of Genes 
and Genomes. 
 
Figure 20: Enrichment Plot: “NK cell cytotoxicity” pathway 
The upper part of the figure shows the running ES for the gene set as the analysis walks down the 
ranked list. A positive ES (the green line is mostly above 0.0) means overexpression. The middle part 
of the figure shows the placement of the individual genes of a certain set in the ranking of all genes. 
Each gene is represented by a line. The bottom part of the plot shows the value of the ranking metric, 
indicating the correlation of a gene to either one of the two phenotypes “substitution” or “deficiency”. It 
is positive (red) when the gene shows higher expression in the phenotype “substitution” and negative 
(blue) when expression is higher in the phenotype “deficiency”. The default GSEA metric signal-to-noise 















IFNA10 interferon, alpha 10 1 0.624 0.2226 
IFNA6 interferon, alpha 6 5 0.436 0.3307 
IFNA4 interferon, alpha 4 6 0.433 0.4379 
IFNA2 interferon, alpha 2 66 0.287 0.4767 
PPP3R2 
protein phosphatase 3 (formerly 
2B), regulatory subunit B, 19kDa, 
beta isoform (calcineurin B, type II) 
76 0.280 0.5202 
RAC3 
ras-related C3 botulinum toxin 
substrate 3 (rho family, small GTP 
binding protein Rac3) 
197 0.215 0.5298 
RAET1L retinoic acid early transcript 1L 310 0.172 0.5312 
IFNA7 interferon, alpha 7 319 0.171 0.5469 
NCR2 
natural cytotoxicity triggering 
receptor 2 
337 0.167 0.5605 
IFNA13 interferon, alpha 13 460 0.143 0.5553 
SHC2 
SHC (Src homology 2 domain 
containing) transforming protein 2 
474 0.140 0.5646 
Abbreviations: ES: Enrichment Score 
Type I interferons are a family of monomeric cytokines consisting of 14 IFN-α subtypes and 
one of IFN-β, IFN-ε, IFN-κ, and IFN-ω and are well identified as antimicrobial but also 
antitumoral substances. Most cell types in the human body can secrete type I IFNs in response 
to activation of TLRs and retinoic acid inducible gene-I-like RNA helicases. Signaling is 
mediated through interferon alpha receptor 1 (IFNRA1) or IFNAR2 and consequent activation 
of the signal transducers and activators of transcription (STAT) signaling complex and the IFN 
regulatory factor (IRF)-9 [104],[170].  
Defects in type I IFN signaling in NK cells leads to reduced NK cell numbers and impaired NK 
cell-mediated cytotoxicity and in turn severely impaired tumor surveillance [104]. Also, NK cell-




4.4.2 Immune System-Related Pathways – Upregulated 
The second part of the analysis involved the entire gene expressions profile received from the 
microarray to look for dysregulated pathways involved in the immune system and vitamin D 
homeostasis. Using the criteria of FDR-value < 0.05, two pathways remained significantly 
upregulated: the “regulation of type I interferon mediated signaling” pathway (Figure 21) and 
the “response to type I interferon” pathway (Figure 22). Table 27 lists the two pathways, which 
showed upregulation. To identify the genes that contribute to the upregulation of these 
pathways, leading edge analysis was performed (Figure 23). There are five interferon genes, 
IFNA2, IFNA4, IFNA6, IFNA7 and IFNA10 showing the highest differential expression within 
these pathways. 
Table 27: Upregulated pathways involved in the immune response 
Name of the Pathway ES NES p-value 
FDR 
q-value 
GO – Regulation of type I interferon mediated  
signaling pathway 
0.78 1.62 0.010 0.032 
GO – Response to type I interferon pathway 0.68 1.56 0.009 0.048 
Abbreviations: ES: Enrichment Score, NES: Normalized Enrichment Score, FDR: false discovery rate, 







Figure 21: Enrichment plot: “Regulation of type I interferon mediated signaling” pathway 
The upper part of the figure shows the running ES for the gene set as the analysis walks down the 
ranked list. A positive ES (the green line is mostly above 0.0) means overexpression. The middle part 
of the figure shows the placement of the individual genes of a certain set in the ranking of all genes. 
Each gene is represented by a line. The bottom part of the plot shows the value of the ranking metric, 
indicating the correlation of a gene to either one of the two phenotypes “substitution” or “deficiency”. It 
is positive (red) when the gene shows higher expression in the phenotype “substitution” and negative 
(blue) when expression is higher in the phenotype “deficiency”. The default GSEA metric signal-to-noise 
ratio was used. 
 
Figure 22: Enrichment plot: “Response to type I interferon” pathway 
The upper part of the figure shows the running ES for the gene set as the analysis walks down the 
ranked list. A positive ES (the green line is mostly above 0.0) means overexpression. The middle part 
of the figure shows the placement of the individual genes of a certain set in the ranking of all genes. 
Each gene is represented by a line. The bottom part of the plot shows the value of the ranking metric, 
indicating the correlation of a gene to either one of the two phenotypes “substitution” or “deficiency”. It 
is positive (red) when the gene shows higher expression in the phenotype “substitution” and negative 
(blue) when expression is higher in the phenotype “deficiency”. The default GSEA metric signal-to-noise 





Figure 23: Leading edge analysis of the upregulated pathways involved in the immune 
response 
Leading edge analysis can be used to highlight common genes in different pathways which show similar 
behavior (up- or downregulation) in gene expression analysis. Vertical bars indicate how often a gene 
appears in the gene sets under investigation. In this case, the maximum possible number of hits was 2, 
since two pathways were examined in this leading edge analysis. The figure shows that the genes of 
IFNA2, IFNA4, IFNA6, IFNA7, and IFNA10 are the common denominator of the two upregulated 
pathways “regulation of type I interferon mediated signaling” and “response to type I interferon”. 
4.4.3 Immune System-Related Pathways – Downregulated 
More pathways were found to be downregulated after vitamin D supplementation. These 
include: “FcεRI” (high-affinity IgE receptor) pathway, “activation of innate immune response” 
pathway, “complement” pathway, “interferon gamma response” pathway, pathway of 
“regulation of interferon beta production”, pathway of ”positive regulation of interferon beta 
production”, pathway of “positive regulation of interferon alpha production”, “leukocyte 
chemotaxis” pathway, “IL6/JAK/STAT3 signaling” pathway, pathway of “activation of immune 
response” and finally “response to vitamin D” pathway (Table 28). Again, leading edge analysis 
was performed (Figure 24). Furthermore, the distribution of common genes between the 






Table 28: Downregulated pathways involved in the immune response 
Name of the Pathway ES NES p-value 
FDR 
q-value 
Biocarta – FCεRI 0.90 1.88 < 0.001 < 0.001 
GO – Activation of innate immune response 0.71 1.87 < 0.001 < 0.001 
Hallmark – Complement   0.70 1.84 < 0.001 < 0.001 
GO – Interferon Gamma response   0.68 1.78 < 0.001 < 0.001 
GO – Regulation of interferon beta production 0.80 1.71 < 0.001 0.002 
GO – Positive regulation of interferon beta production 0.86 1.70 < 0.001 0.002 
GO – Leukocyte chemotaxis 0.67 1.64 < 0.001 0.013 
GO – Positive regulation of interferon alpha production 0.89 1.59 0.002 0.032 
Hallmark – IL6/JAK/STAT3 signaling 0.66 1.58 < 0.001 0.032 
GO – Activation of immune response 0.57 1.57 < 0.001 0.032 
GO – Response to vitamin D 0.77 1.57 0.012 0.031 
Abbreviations: ES: Enrichment Score, NES: Normalized Enrichment Score, FDR: false discovery rate, 
GO: Gene Ontology 
 
Figure 24: Leading edge analysis of the downregulated pathways involved in the             
immune response 
Leading edge analysis can be used to highlight common genes in different pathways which show similar 
behavior (up- or downregulation) in gene expression analysis. Vertical bars indicate how often a gene 
appears in the gene sets under investigation. In this case, the maximum possible number of hits was 
11, since eleven pathways were examined in this leading edge analysis. The figure shows the 






Figure 25: Common gene distribution among the downregulated pathways 
This heat map shows the distribution of common genes among the downregulated pathways. Color 
intensity is analogous to the magnitude of reduced gene expression after vitamin D substitution, with 
rose demonstrating weaker and dark red stronger relative downregulation.  
First, some selected downregulated pathways will be briefly described.  
FcεRI (high-affinity IgE receptor) pathway: FcεRI is the major receptor for mast cell activation 
and its activation results in NF-kappa B activation and proinflammatory cytokine production 
[71]. A relationship to NK cells is not known. 
Complement has been shown to promote complement-dependent cytotoxicity (CDC) which is 
a distinct and ADCC-independent mechanism of cytotoxicity. However, experimental models 
demonstrated that complement inhibition increases the availability of NK cells within neoplastic 




therefore been suggested, that the complement pathway could be a potent therapeutic target 
to improve NK-dependent antitumoral immune responses in cancer immunotherapy [62,63]. 
The IL-6/JAK/STAT3 signaling pathway: has been shown to be aberrantly hyperactivated in 
patients with chronic inflammatory conditions and in those with hematopoietic malignancies or 
solid tumors. Furthermore, cell types in the tumor microenvironment including NK cells show 
STAT3 hyperactivation. It has been hypothesized, that therapeutic targeting of components of 
the IL-6/JAK/STAT3 can inhibit tumor cell growth and relieve immunosuppression in the tumor 
microenvironment. Specifically for NK cells, inhibition of IL‐6‐JAK/STAT3 signaling has been 
proven to increase the NK cell-mediated cytotoxicity against castration‐resistant prostate 
cancer cells [65,160]. 
IFN-γ response: This pathway involves genes which are known to be up-regulated in 
response to IFN-γ stimulation. Its function is described in 4.3.3, page 64. 
We could also demonstrate the downregulation of the response to vitamin D (Figure 25) 
pathway, as to be expected in the context of a vitamin D supplementation. Downregulated 
genes involved in this pathway included PLA2G4A, TNC, SFRP1, CYP27B1, FZD1, INSR, 
ALPL, PTGS2 and CD4. 
 
Finally, a close examination of Figure 25 and Figure 24 reveals a gene cluster which was 
found to be overrepresented in the significantly downregulated pathways. This cluster involves 
three toll-like receptor genes, TLR2, TLR7 and TLR8. Furthermore, TLR 5 and TLR10 were 
also represented in the leading edge analysis, however less commonly represented in the 
pathways above. TLR genes expression of all subjects is shown in Figure 26. However, and 







Figure 26: TLR gene expression in all subjects 
Selected TLR gene expression before (blue columns) and after (red columns) vitamin D 
supplementation across all subjects. Standard deviation is shown as error bar. The unadjusted 
p-values according to two-way ANOVA are given above each pair of columns. Across all 
subjects, of the five TLR genes, TLR5 and TLR8 were downregulated (p-value < 0.05) after 
vitamin D supplementation. 
  
Figure 27: TLR gene expression in females 
Selected TLR gene expression before (blue columns) and after (red columns) vitamin D 
supplementation in female subjects. Standard deviation is shown as error bar. The unadjusted 
p-values according to two-way ANOVA are given above each pair of columns. In addition to 
TLR5 and TLR8, TLR2 was also downregulated in female NK cells after vitamin D 




































































4.4.4 Unsupervised Pathway Analysis 
As a final step, an unsupervised pathway analysis was performed using the Genetrail web tool. 
The pathway databases analyzed were the ones on the default setting of the Genetrail 
algorithm. An adjusted p-value of < 0.01 was selected for significance, corrected according to 
the Bonferroni method. In total, six pathways were found to be enriched and five were depleted 
after in vivo supplementation of vitamin D. More detailed results are given in Table 29 sorted 
by gene set database. 




GO – Cellular Component 
downregulated ubiquitin ligase complex 7.10E-003 
GO – Biological Process 
upregulated 
detection of chemical stimulus involved in sensory 
perception of smell 
1.03E-005 
upregulated sensory perception of smell 3.50E-005 
upregulated 
detection of chemical stimulus involved in sensory 
perception 
4.12E-005 
downregulated biological phase 9.56E-003 
GO – Molecular Function 
upregulated olfactory receptor activity 3.01E-006 
downregulated ubiquitin like protein ligase activity 2.56E-003 
downregulated ubiquitin protein ligase activity 2.56E-003 
KEGG - Pathways 
upregulated olfactory transduction 07.50E-007 
Reactome - Pathways 
upregulated olfactory Signaling Pathway 6.29E-006 
downregulated generic Transcription Pathway 1.94E-005 
This figure lists the pathways which were found to be upregulated (in bold) or downregulated 
in the unsupervised analysis. They are listed according to the reference database they were 
obtained from, which is reported in the gray lines (also see chapter 3.4.4 page 37). 
A downregulation of ubiquitin ligase pathways was observed. Ubiquitination is a post-
translational modification of proteins that involves the addition of ubiquitin to a target protein 
and is necessary for several cellular processes, like protein degradation by the proteasome, 
cell cycle progression, transcriptional regulation, DNA repair, and signal transduction. For 




ubiquitin-conjugating enzymes and E3 ubiquitin ligases [7]. Table 30 lists the genes of the 
ubiquitin ligase complex family which were found to be significantly (p < 0.05) downregulated. 
Ubiquitin ligases mediate the inhibition of NK-cell activity [100]. Furthermore, the 
downregulation or knockout of ubiquitin ligases has been directly connected to enhanced NK 
cell antitumor activity in several studies [94,100]. 
Olfactory receptors are expressed in immune cells [97], but their role in NK cells remains 
unclear. Their participation in hapten recognition has been hypothesized but not confirmed 
[50]. The results of such unguided analysis must be interpreted with caution and with critical 
assessment of their biological relevance. 







FEM1C fem-1 homolog c (C. elegans)  1.15 0.00928 
ANAPC4 anaphase promoting complex subunit 4  1.11 0.00962 
DCAF12L2 DDB1 and CUL4 associated factor 12-like 2  1.21 0.01035 
MED17 mediator complex subunit 17  1.15 0.01044 
DCAF16 DDB1 and CUL4 associated factor 16  1.10 0.01046 
CACYBP calcyclin binding protein  1.30 0.01730 
PCGF5 polycomb group ring finger 5  1.16 0.01815 
GLMN glomulin, FKBP associated protein  1.12 0.01923 
DCUN1D2 
DCN1, defective in cullin neddylation 1, 
domain containing 2  
1.15 0.02081 
RCHY1 
ring finger and CHY zinc finger domain 
containing 1, E3 ubiquitin protein ligase  
1.21 0.02507 
NCCRP1 
non-specific cytotoxic cell receptor protein 1 
homolog (zebrafish)  
1.16 0.02847 
RNF149 ring finger protein 149  1.13 0.03074 
SUGT1P3 
SGT1 homolog, MIS12 kinetochore complex 
assembly cochaperone pseudogene 3  
1.34 0.03128 
UBE2U ubiquitin-conjugating enzyme E2U (putative)  1.13 0.03664 
FBXO21 F-box protein 21  1.13 0.04002 
MED14OS MED14 opposite strand  1.14 0.04334 
ATG3 autophagy related 3  1.12 0.04780 





The NK cells used in this study had demonstrated a significantly increased ADCC activity 
against the lymphoma cell line DAUDI in the presence of Rituximab under physiologically 
normal vitamin D serum concentrations or after supplementation of vitamin D in vivo, 
respectively [20,105]. Thus, the aim of this study was to investigate the molecular mechanisms 
of the influence of vitamin D on NK-cell activity. To this end, in this thesis mRNA expression 
profiles of NK cells were compared before and after supplementation of vitamin D in vivo. 
5.1 ROLE OF PATHWAY ANALYSIS IN GENOMIC RESEARCH 
In modern genome research DNA and cDNA microarrays and more recently next generation 
sequencing are part of daily practice. A widespread problem faced with gene expression 
profiling is the lack of statistical significance of individual genes after correcting for multiple 
testing. The level of differential expression may be discreet compared to the level of “false 
positive background” which always happens with such amounts of data. On the other hand, 
successfully identified differentially expressed genes, which not necessarily share biological 
functions, may cause a certain bias in interpreting the data under biological aspects. 
Furthermore, pure mathematical search for a single highly expressed gene may miss crucial 
subtle changes concerning a whole pathway, whose individual gene differential expression 
may not reach statistical significance after correcting for multiple testing. Considering biological 
or functional aspects it is clear, that changes concerning a complete pathway are much more 
interesting than just one single gene. Traditional methods to examine statistical significance 
would miss such a difference. Moreover, it has been shown that investigating individually 
expressed genes often leads to different results when different scientists were studying the 
same biological system.   
To address this problem in the context of big data, several statistical methods have emerged. 
Some examples include Over Representation Analysis (OSA) [44], Gene Set Enrichment 
Analysis (GSEA) [138] and GO-Bayes, a gene ontology based overrepresentation Bayesian 
analysis. 
GSEA is a method of statistical analysis which evaluates high-throughput microarray data at 
the level of gene sets. These gene sets are assembled based on already published, widely 
accepted data on pathways or co-expression shown in previous experiments. GSEA can be 
used to compare samples belonging to two classes, in our case the (vitamin D) deficient 
phenotype (suffix “a”) and the phenotype after vitamin D substitution (suffix “b”). Based on their 
differential expression as assessed by any suitable metric between the two different classes, 
at first a ranked gene list was generated. For the second step, a predefined gene set is 




pathway or belonging to the same GO category). GSEA determines then if the members of the 
predefined gene set are randomly distributed throughout the ranked gene list, or primarily 
found at the top or at the bottom of the list. Gene sets whose distribution lies closely to a 
particular phenotype (top or bottom of the list) are considered to be related to the specific 
phenotype. The extent of the correlation with a specific phenotype is measured with the 
enrichment score. A level of significance for the enrichment score was calculated additionally 
by using permutation techniques. Finally, the estimated significance level is adjusted for 
multiple testing. 
There are several tools provided online to be used for pathway analysis. GeneTrail is a web-
based application developed at the Saarland University, which allows the identification of 
enriched functional categories within protein or gene sets. Both OSA and GSEA are available 
in the algorithm, as well as a novel dynamic-programming algorithm that improves the p-value 
computation of GSEA methods [10]. 
 
Our results based solely on the comparison of single genes before and after supplementation 
were at first sight quite sobering, because, after correction of the expression data for multiple 
testing, no significant dysregulation of a single gene could be found. This result implies that a 
direct effect of supplementation in vitamin D deficient individuals on the NK-cell transcript is 
limited. However, the main reason for this result is certainly the small number of subjects 
included in the study of only eight people, leading inevitably to statistically extremely weak 
outcomes. Therefore, the problem of a "large P" combined with a "small N" had a strong impact 
as referred before (4.2.2, page 47). Thus, it can still be assumed that the expression 
differences, irrespective of the extent of their statistical significance have a certain relevance 
for the increase in NK-cell activity after vitamin D supplementation. With this in mind, a number 
of mechanisms seem relevant of discussion. 
5.2 ALTERED CYTOKINE - mRNA PROFILE AFTER VITAMIN D SUPPLE-
MENTATION 
The IFG gene, which encodes IFN-γ, was shown to be downregulated after vitamin D 
supplementation, with this effect being of particular magnitude in male subjects. IFN-γ 
modulates the immune response, in particular against intracellular bacteria, viruses and tumor 
cells. It is secreted by NK cells, NKT cells, cytotoxic CD8+ T cells and Th1 CD4+ T cells. 
Although its effect on cells on the immune system include stimulating Th1 differentiation, 
promoting leukocyte chemotaxis and enhancing macrophage functions [112]. IFN-γ also plays 
a central role in chemotaxis of NK cells in tumors and their accumulation at the site of infection 




improved survival in some cancer types, for example in colon cancer [37]. Additionally, IFN-γ 
leads to ICAM-1 upregulation on the target cell which facilitates NK cell binding to the target 
cell [154].  
On the other hand, tumor cells overexpress inhibitory ligands like PD-L1, CD95 (FasR), and 
CD270 (HVEM) in the presence of IFN-γ, which may reduce T-cell responsiveness [6]. 
Moreover, increased IFN-γ levels also lead to stronger expression of MHC-I molecules on 
target cells. However, MHC-class I molecules are also inhibitory ligands for NK cells. Thus, 
when expressed on cells targeted by NK cells, for instance tumors, MHC-I molecules could 
lead to reduced NK cell-mediated killing. In fact, in vitro experiments have shown that in some 
tumors, the presence of IFN-γ leads to decreased NK cell-mediated tumor lysis. Specifically, 
leukemia and lymphoma cell lines appear to be protected from NK-cell activity in the presence 
of IFN-γ [6]. In this context, the downregulation IFN-γ is consistent with the finding of increased 
NK-cell-mediated ADCC in vitro against the lymphoma cell line DAUDI. 
Another cytokine axis appears to be affected by vitamin D supplementation. IL-2 has been 
linked to NK-cell activation as early as 1981 [54]. The IL-2 receptor (IL-2R) is composed of 
three subunits α (CD25), β (CD122), and γ (CD132) [163]. The gene encoding the β-chain of 
the IL-2 receptor (CD122) was shown to be upregulated. Thus, vitamin D could be involved 
in priming NK cells for activation. At this point it must be emphasized, that the NK cells used 
in this study where not pretreated with IL-2. Lastly, another gene which has been shown to 
suppress IL-2 production in T cells, NFATC4, was downregulated after vitamin D substitution.  
Thus, both the upregulation of CD122 and the weaker expression of NFATC4 are consistent 
with an increased NK cell/ADCC activity after vitamin D administration. 
Moreover, the receptor of another cytokine, the IL-17 receptor was also shown to be 
upregulated. IL-17 is linked to a rise in circulating NK cells and an increased expression of 
perforin and granzymes and cytolytic function [4]. As with the cytokines and their receptors 
mentioned above, the increased expression of IL-17R by vitamin D in the context of its 
described functions can also explain an increased NK-cell/ADCC activity. 
The role of type I and type III interferons and their regulatory axes, however, are even more 
important. Several interferons of these gene families are upregulated in our experiment. In 
addition to various genes encoding IFN-α isoforms (IFNA2, IFNA4, IFNA6, IFNA7, and 
IFNA10) also IFNL3 (encoding IFN-λ3). Although the expression of these individual genes 
does not vary statistically significantly after supplementation, the cumulative expression 
differences of the respective gene families are significant. This also applies to the individual 
genes combined in pathways involved in different immune responses. 
Type I interferons are cytokines which play a role in host defense against viruses but also in 




ε, as well as IFN-. They can be produced by most human cells through PRR recognition such 
as TLRs. Downstream signaling is mediated by IFNAR inducing STAT1/2 and IRF9 activation. 
The latter form a complex called interferon-stimulated gene factor 3 or ISGF3 [104],[170]. In 
IFNAR-knockout mice, incapable of IFN-α signaling, lower NK-cell numbers were observed as 
well as reduced NK-cell-mediated cytotoxicity and consequently increased susceptibility to 
fibrosarcoma and lymphoma [104]. Beyond that IFN-α also stimulates DCs to produce IL-15 
which promotes NK-cell development, proliferation, and function. 
The type III interferon family includes four members: IFN-λ1 (IL-29), IFN-λ2 (IL-28A), IFN-λ3 
(IL-28B), and IFN-λ4. Their signals are transmitted via the IFN-L receptor, which in turn 
activates ISGF3, similar to type I interferons. Thus, they not only influence NK-cell responses 
against viruses, but also play an important role in NK-cell-mediated tumor surveillance. IFN-λ 
enhances T- and NK-cell responses against tumors like melanoma, lung cancer, and breast 
cancer. IFNLR1-/- NK cells have reduced tumor suppressing capacity in vivo [83]. Hence, an 
increased expression of IFN-α subtypes and IFN-λ3 may again explain the increased 
rituximab-mediated NK-cell cytotoxicity after vitamin D substitution in deficient individuals. 
5.3 ALTERED PATHWAYS AFTER VITAMIN D SUPPLEMENTATION 
Downstream signaling upon IL-2R activation involves the MAPK pathway [33]. This pathway 
in important for mediation of intracellular activation signals in NK cells and encompasses three 
kinase families: ERK, p38, and JNK [127]. A gene encoding one of the components of the JNK 
family, MAP4K1, was found to be upregulated after taking vitamin D. This kinase family is 
required for NKG2D-mediated NK-cell activation [85]. However, the NK-cell-mediated ADCC 
is described as being specifically mediated by the P38 and ERK families [146], whose 
members not have been affected by vitamin D in our experiments. The vitamin D-induced 
increased expression of MAP4K1 from the JNK family may explain the increased natural NK-
cell activity after supplementation. However, the equally increased ADCC activity of NK cells 
after vitamin D ingestion would be more consistent with an increased expression of members 
of the P38 or ERK families. However, it remains to be clarified whether MAP4K1/NKG2D-
mediated NK-cell activation has a higher priority compared to ADCC signaling. 
Even if for most humans in our geographical latitudes particularly over the winter and spring 
months a vitamin D undersupply or even a more or less complete deficiency is considered as 
normal, the question remains, how our immune system evolutionarily adapted itself to this 
chronic undersupply and/or to this deficiency. Apart from a significant increase in influenza 
infections, some of which are serious, and clinically hardly relevant flu infections of the 




period. However, both the incidence of cancer and cancer associated mortality are increased 
during the winter. This observation has been associated with the seasonal variation of vitamin 
D levels [102]. 
The results of this study show for the first time an option how NK cells can compensate the 
IFN pathways of type I and III, which are weakened under vitamin D deficiency. The secretion 
of these cytokines, which are essential for NK-cell activity, is also regulated by toll-like 
receptor-mediated signals [53]. Thus, the stimulation of TLR5 induces the synthesis of IFN-
l [166]. Increased expression of different TLRs (such as TLR2, TLR5, TLR7 and TLR8) in 
vitamin D undersupply or deficiency increases the signal flow via these receptors and thus can 
compensate for the "simultaneous" weaker expression of the IFN-I/III pathway. The MAPK 
pathway described above is also associated with TLR activation and cytokine production [118]. 
It is just as contracyclical of vitamin D as the TLR pathway. If vitamin D deficiency is 
compensated, in our study by in vivo supplementation with DekristolTM or by increasing the 
body's own synthesis during summer, compensation of the synthesis of type I and III 
interferons is no longer necessary. The expression of the corresponding pathways of TLR and 
MAPK are reduced. 
The downregulation of the ubiquitin-ligase pathways is of particular biological significance in 
the context of the changes observed so far. High quality data support the fact that genetic 
deletion or inhibition of the E3 ubiquitin-ligase casitas B-lineage lymphoma-b (Cbl-b) unleashes 
the antitumor potential of NK cells leading to control of tumor metastatic spread in mice [94]. 
Other E3 ligases have also been shown to inhibit NK-cell functions [42]. Kaposi's sarcoma-
associated herpesviruses encoding E3 ubiquitin-ligases are able to evade NK-cell activity 
[143]. Others have suggested an interaction of KIRs and ubiquitin ligases in NK-cell inhibition 
[100]. Ubiquitin-ligases does not only play a role in inhibiting the NK cells in general, but also 
specifically in regulating the TLR/IFN axis. Ubiquitin ligases have been shown to inhibit TLR 
signaling of the nuclear factor (NF)-kB [29], and their knockdown led to higher levels of 
proinflammatory cytokines in an animal model via the TLR/IL-1R/TRAF6 pathway [168]. 
Production of IFN-α upon TLR stimulation is known to depend on the formation of a complex 
consisting of MyD88, IRF7, and TRAF6 as well as TRAF6-dependent ubiquitination [70]. 
Others inhibit type I IFN secretion through IRF3 and IRF7 ubiquitination [164] or through 
inhibition of retinoic acid-inducible gene I (RIG-I) and TRIM25 [58]. 
One connected pattern becomes apparent: the ubiquitin-ligase pathway, a negative regulator 
of type I interferon synthesis, becomes downregulated after supplementation with vitamin D 
leading to increased IFN-α production. The overexpression of TLRs in the vitamin D deficient 
state could be explained as a compensatory mechanism of the downstream suppression of 







Figure 28: Proposed model of effect of vitamin D deficiency and supplementation on NK 
cells 
In the state of vitamin D deficiency signaling pathways leading to IFN-α production are reduced 
due to an increased activity of the ubiquitin-ligase system. This leads to an overexpression of 
toll-like receptors. Once vitamin D levels are restored, the ubiquitin system is downregulated 
and therefore IFN-α production is restored. Compensatory toll-like receptor overexpression is 





5.4 INDIRECT INFLUENCE OF VITAMIN D ON NK CELLS 
Another approach to explain the changes observed in the NK-cell mRNA profile after vitamin D 
supplementation would be, if it is not the NK cells themselves which are direct targets of 
vitamin D, but another, “mediator” cell, like macrophages or DCs, which in turn directly 
influence the NK cells. The effect of 1,25(OH)2D3 on monocytes/macrophages is well 
established and described in detail in section 2.2.7 on page 12. This assumption is further 
supported by the fact that some of the genes/gene sets appearing to be dysregulated have no 
known role in NK cells, for example the FcεRI pathway, the C1orf147 gene as well as other 
genes like PSMC6, SRSF1, SLPI, VAMP2, CCR10, and PADI4. Supportive of this notion, a 
comparison of our data set with known vitamin D-responsive genes in monocytes revealed 
several genes that are dysregulated in our experiment as well: The COQ3, DENND6B, 
EPB41L1 and ITGAM genes [107]. 
Depending on the target cell, vitamin D also unfolds different immunomodulatory effects [12]. 
In vitro incubation with 1,25(OH)2D3 leads to reduced maturation of DCs and inhibits their 
capacity to express co-stimulatory molecules leading to reduced capacity of the DCs to activate 
T cells, as determined by decreased proliferation and IFN-γ secretion in mixed leukocyte 
cultures [115]. Other studies have also demonstrated lower TLR4 expression on the NK-cell 
surface as well as decreased TNF‐α and IFN‐γ production in NK cells after in vitro incubation 
with 1,25(OH)2D3. A direct effect of 1,25(OH)2D3 through NF‐κB phosphorylation was 
postulated as mechanism behind these findings [110]. In addition, these expression changes 
induced by substitution in vitro are consistent with those in our study after in vivo 
supplementation. Thus, our findings of downregulation of pathways such as “activation of 
immune response”, “complement,” “interferon gamma response”, and “leukocyte chemotaxis” 
can also be interpreted in the context of the immunomodulatory/-suppressive function of 
vitamin D. 
5.5 ROLE OF SEXUAL DIMORPHISM 
The immune system of female and male mammals has been shown to have well defined 
differences, a phenomenon called sexual dimorphism. Females recover better from infections, 
sepsis and trauma than males [171]. This is due to the fact that they are able to mount more 
efficient immune response [99]. It is therefore not surprising that they also suffer more 
frequently from autoimmune diseases [16]. Furthermore, not only do men have a higher 
incidence of cancer, but the survival rate is lower in men than in women with the same cancer 
[36]. The female immune system is more effective than the male immune system and this is 




cell-mediated immune responses [48]. A study comparing NK-cell activation in elderly men and 
women found higher ratios of immature CD56bright to mature CD56dim NK cells, increased IFN‐
γ response, and enhanced cytotoxic granule responses to K562 leukemia cells in elderly 
females [3]. Next to social, occupational, and behavioral factors, there are also well defined 
differences on molecular and cellular level which can explain sexual dimorphism. 
First, sex hormones directly influence different effector cells. Estrogen exposure has been 
linked to increased IgG/IgM production in B lymphocytes and in other studies to increased IFN‐
γ and IL-2 production in T cells. Similarly, IL-6 secretion is stimulated in dendritic cells but 
halted in monocytes by estrogen. In NK cells, several studies have demonstrated a dose 
dependent effect of estrogens with high dose rates lead to suppression of NK-cell activity [109]. 
Another important aspect are chromosomal differences between both sexes. Thus, males 
possess a unique set of genes on the Y-chromosome. On the other hand, some genes on the 
second X-chromosome in females may escape inactivation which results in an increased 
expression of the respective gene(s) [116]. Two of these genes are TLR7 and TLR8. Their 
higher expression in females has been explained by incomplete X inactivation [113]. As a 
result, higher IFN-α levels have been shown in female-derived PBMCs compared to males 
[18].  
In our experiment, higher expression of the JPX gene could be demonstrated after vitamin D 
substitution in females. JPX (Xist) is a long non-coding RNA which is located on the X-
inactivation center and is involved in X-chromosome inactivation in female mammals [141]. 
This could lead to inactivation of previously active areas on the second X-chromosome. As it 
was demonstrated before, TLR7 mRNA levels were also lower in our experiments after 
supplementation of vitamin D in vivo. TLR8, which is also expressed on the X-chromosome 
was similarly downregulated after vitamin D substitution. This effect was more significant in 
female subjects. This demonstrates a clear pattern: Vitamin D supplementation restores 
epigenetic control over the X-inactivation center through increased JPX expression in females 
and leads to reduced TLR7/8 expression. This would argue for a staggered influence of vitamin 
D on gene expression: Target genes whose expression is directly influenced by vitamin D and 
then downstream genes whose expression is indirectly regulated by the primary vitamin D 
targets. Sexual dimorphism cannot however account for the full extent of the changes 
observed in our experiment. TLR2 and TLR5 are located on chromosomes 4 and 1 
respectively, and a mechanism which involves X-chromosome-dependent regulation could not 
be identified until now. 
One other sex-specific gene with vitamin D dependency was highlighted in our experiment: 
RPS4Y1, located on the Y-chromosome. Its expression in males was reduced after vitamin D 




ribosomal protein to be encoded by two genes [172]. In contrast to our results, a recent 
randomized controlled double-blind clinical trial looking at the effect of vitamin D 
supplementation on buffy coat gene expression demonstrated overexpression for the Y-linked 
RPS4Y1 gene after supplementation [128]. In addition to the overexpression of RPS4Y1 after 
vitamin D treatment, Shirvani's study also found significantly altered expression in more than 
1,000 additional whole genome genes with an increasing trend under continued 
supplementation. The reason for this, as a start, contradictory result, is quite certainly that in 
this study the PBMC of the test persons were examined. That means that apart from the NK 
cells, whose portion of the PBMC amounts to approx. 5 %, also monocytes and lymphocytes, 
e. g. T cells (CD4 and CD8) and B cells, were under the influence of Vitamin D. Thus, in the 
study by Shirvani et al. one or more of these non-NK populations were responsible not only for 
the overexpression of RSP4Y1 but also for the principally higher genome wide vitamin D 
sensitivity. In this respect, the results of Shirvani et al. support the above described assumption 
that the influence of vitamin D on NK cells is (also) indirectly mediated via other cells that are 
under a more stringent influence of vitamin D, and that not all genes are affected to the same 
extent (chapter 5.4, page 89). Another difference between our study and that of Shirvani et al. 
is that Shirvani and colleagues used a protocol for vitamin D supplementation that was quite 
different in terms of dose and schedule. Thus, the average of about 30 ng/ml 25-OH(D) in 
serum was achieved by application of a low dose of cholecalciferol over several weeks. This 
resulted in a significantly longer response time for the vitamin D sensitive cells. To achieve 
mean normal serum levels of approximately 65 ng/ml 25-OH(D) within two weeks we 
administered up to 100,000 I. U. cholecalciferol over only 5-6 days with a further 4-5 days 
adaptation period (chapter 3.1.3, page 15). It is possible, that a longer lasting influence of 
appropriate vitamin D levels on NK cells would enhance the rather subtle effects we observed 
in our study. 
5.6 VITAMIN D IN THE CONTEXT OF AUTOIMMUNITY AND CHRONIC 
INFLAMMATION 
Next, the relation between vitamin D deficiency and autoimmunity / chronic inflammation has 
to be discussed in the context of our findings. Vitamin D deficiency has been linked in 
epidemiological studies with increased incidence of autoimmune diseases like diabetes 
mellitus type I, systemic lupus erythematosus (SLE), multiple sclerosis, inflammatory bowel 
disease, and rheumatoid arthritis [12]. Specifically in SLE the overactivation of the TLR/IFN-
/ axis has been given pathophysiological importance [13]. However, as in other trials, 
supplementation did not lead consistently to better disease control, although higher doses 




atherosclerosis, and TLR4 or MyD88 knockout protected mice from atherosclerosis [101]. This 
last quoted association between TLR4 knock out and a reduced incidence of atherosclerosis 
is consistent with the result of our study showing a significantly reduced TLR expression after 
vitamin D supplementation and the finding that chronic inflammation/autoimmunity is 
associated with vitamin D deficiency. Another, alternative hypothesis arises around the 
overexpression of TLR receptors in the vitamin D deficient state (which is per definition the 
“pathological” state): Their high expression contributes to a state of immune “overreaction” and 
predisposes to autoimmunity. This pathological “overexpression” is corrected after vitamin D 
serum concentration is restored to the physiological/normal level. 
5.7 CRITICAL VIEW AND OUTLOOK 
Our study also reveals some weak points that probably had an impact on the results.  
It has been repeatedly described before that a combination of a large number of investigated 
objects (in our case transcripts) in investigations of only a small cohort of test subjects, the so-
called "large P/small N" situation, significantly strains the statistical significance of the results 
thus determined. However, it is difficult to recruit a larger number of volunteers from the 
immediate environment who are willing to participate in intervention studies. In addition, a 
vitamin D deficiency is limited to the few winter months only. As described in chapter 4.2.1, 
page 41, after supplementation only a very small number of the total 40,716 transcripts have 
an altered expression and, moreover, mostly concerning genes that are located in a suitable 
immunological context. Only after stringent correction for multiple testing, the p-values 
increased above 0.05. And the pathways mentioned above showed a significantly altered 
expression compared to the deficiency state, even after final stringent correction.  
There is still another point that also must be discussed critically. Namely that we used resting 
NK cells for RNA extraction. It is well established that in vitro cytokine activation of NK cells 
has consequences on their phenotype, cytokine expression profile, and most importantly on 
their transcriptome [25]. It can therefore be assumed that some changes at the transcriptional 
level in the NK cells of our study after vitamin D treatment were too weak to be classified as 
significant. Other changes probably even remained entirely undetected. Possibly, the vitamin 
D-induced transcriptome alteration in NK cells would have been more significant after 
activation on their target cells before as well as after supplementation. The microarray used in 
this study provided broad transcriptome coverage. Thus, we refrained from additional testing 
for expression of receptors on the NK-cell surface or analysis of cytokine levels. We assumed 
that an increase/decrease in protein production is reflected in the transcribed mRNA levels. It 
is possible, that effects induced by RNA molecules with very small half-life, such as small 




ubiquitin-ligase complex mRNA expression allows us to assume changes in the post-
translational modification after vitamin D supplementation, however our RNA-based approach 
does not allow further examination. 
In genome wide expression studies which involve a large number of genes, a number of false 
positive results must always be expected. These may be reflected in some of the 
genes/pathways mentioned above (chapter 5.4, page 89) like the FcεRI pathway, which, under 
biological aspects, seem to fall out of context. 
Despite of these limitations, this study showed at which points or via which pathways vitamin 
D can influence the activity of NK cells or safely does so. This results in possible starting points 
on which further investigations of this question should focus. For instance, it would be 
interesting to examine if the effect of increased NK cell-mediated ADCC after vitamin D 
supplementation is inhibited in the presence of IFN-α or IFN-λ antibodies. Furthermore, 
interference studies with siRNA targeting different TLRs or E3 ubiquitin-ligase genes could 
shed more light into the effect of vitamin D on NK-cell cytotoxicity. 
5.8 CONCLUSION 
To summarize, this study shows that vitamin D supplementation has an effect on the 
transcriptome of resting NK cells, but this effect was rather small. The results indicate the 
involvement of the TLR/IFN-α/λ axis and its regulation through the ubiquitin-ligase system. 
Furthermore, we demonstrate that differences in TLR expression are to some extent sex-
specific and imply a role for vitamin D in JPX-mediated X chromosome deactivation. 
Immunomodulatory and immunosuppressive effects are also observed. It is also probable, that 
vitamin D does not exert its main effect on the NK cells directly, but the effect could be mediated 
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